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ABSTRACT OF THE DISSERTATION

Role of mTORC1 and Autophagy in the Regulation of
Fludarabine-resistance in Leukemic B-cells

By Arishya Sharma

Deregulated mTORC1 contributes to tumorigenesis and chemoresistance.
However, mTORC1-specific inhibitors (rapalogs) show modest efficacy in the
clinic, as they unleash the feedback inhibition on upstream, prosurvival
pathways. An alternative approach is to target downstream functions of
mTORC1. We investigated acquired resistance to fludarabine (Flu), a purine
analog, active agent for chronic lymphocytic leukemia (CLL). Elevated phosphop70S6k (T389), an mTORC1 activation marker, predicted Flu resistance in a
panel of B-cell tumor lines, and primary CLL cells. However, the rapalogs
induced moderate cell death in Flu-resistant (FluR) and primary CLL cells.
Activation of oncogenic pathways, including mTORC1, induces profound
metabolic reprogramming to provide energy and biosynthetic substrates for
x

tumor growth. Therefore, we investigated the metabolic consequences of
mTORC1 activation in FluR compared to Flu-sensitive (FluS) cells, aiming to
identify selective vulnerability of FluR cells to interference with specific metabolic
pathways (Aim1). Seahorse metabolic analysis revealed mTORC1-mediated
increase in glycolysis and mitochondrial respiration, which was uncoupled from
ATP synthesis in the FluR cells. Additionally, we observed increased mTORC1p70S6k dependent phospho-CAD (S1859) and, S-phase population in FluR cells,
suggesting accelerated de novo pyrimidine biosynthesis. Consistently, siRNAmediated knockdown of p70S6K, and the pharmacological inhibition of the
enzymes

of

de

novo

pyrimidine

biosynthesis

pathway,

or

associated

mitochondrial respiration were selectively cytotoxic to FluR, but not FluS cells.
Such oncogene-mediated metabolic reprogramming confers selective
growth and survival advantage to cancer cells.

However, the by-products of

unrestrained biosynthesis and exhaustive mitochondrial metabolism will cause
metabolic stress. Autophagy, by removal and recycling of damaged cellular
contents, functions as a prominent cellular metabolic stress adaptation pathway.
This suggested autophagy might be critical in FluR cell survival. Given the dual
role of autophagy, pro-death or –survival, we investigated the context-dependent
role of autophagy in FluS and FluR backgrounds (Aim2). Consistent with the
prosurvival role of autophagy under metabolic stress, FluR were addicted to
AMPK-dependent, and BECN1-independent autophagy. In FluS cells, Fluinduced cell death associated, BECN1-dependent autophagy. Therefore, we
propose (i) upstream stimuli, such as overstimulation by chemotherapy treatment

xi

versus stimulation by metabolic stress within cellular threshold limits, and (ii)
molecular regulatory inputs, BECN1-dependent versus AMPK-dependent, could
be determining factors for pro-death versus pro-survival function of autophagy.
Overall, our data support the hypothesis that targeting downstream
functions of mTORC1, including pyrimidine biosynthesis, glucose metabolism,
and autophagy in cells with deregulated mTORC1 could be an important and
effective means to bypass rapalog resistance. We establish that mTORC1,
metabolic reprogramming and, autophagy, are critical determinants of Fluresistance. Future studies delineating the mechanistic links between these three
pathways are expected to yield fruitful insights into the understanding of
chemoresistance in cancer.
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CHAPTER I
INTRODUCTION
1.1 Overview of mTOR pathway
Rapamycin (or sirolimus, the prototypical inhibitor of molecular target of
rapamycin (mTOR) was serendipitously discovered as an antifungal agent in the
soil of Rapa Nui in 1975 (1). Since then, the mTOR inhibitors have continued to
attract researchers as well as clinicians. Almost 40 years of magnificent
research, including the recent mTOR omics—ribosome profiling, transcriptomics,
metabolomics, and phosphoproteomics, has revealed that mTOR is the central
growth and proliferation regulatory kinase (1). It integrates the inputs from major
upstream growth and survival regulating stimuli, including— growth factors,
energy, oxygen, amino acids, and cellular stress such as DNA damage to the key
downstream pathways needed to sustain and grow, including—protein
biosynthesis, nucleotide biosynthesis, lipid metabolism, glucose metabolism,
autophagy, apoptosis, and cell cycle (2, 3). Clearly, to understand cell growth
and survival, elucidation of function and regulation of mTOR is a key.

1

Conversely, deregulated mTOR signaling is frequently associated with
development and drug resistance in cancer, metabolic, neurological, and genetic
disorders (4). Yet, disappointingly the pharmacological inhibition of mTOR by
rapamycin, especially in cancer treatment has shown modest efficacy in clinic,
except for patients with renal cell carcinoma-, tuberous sclerosis complex -, and
lymphangioleiomyomatosis -related tumors (1). This critical question has been
widely studied, and activation of pro-survival feedback loops and compensatory
pathways in response to mTORC1 inhibition have been implicated in the
phenomena (1).
Current research in the field focuses on development and investigation of
such dual inhibitors in the market that co-target both mTORC1 and these
interfering pathways, especially PI3K, and various combination treatments are
being investigated (1, 5). While such strategies are expected to improve the
clinical efficacy, given the overwhelming networking of mTORC1, efforts are
needed to develop better strategies to effectively exploit this pathway in the
clinic. In this regard, investigation of the most “vulnerable" signaling pathway(s) in
a given disease setting, not necessarily upstream or parallel, but also
downstream of mTORC1 should be addressed. The future expects to see in the
clinic mTORC1 inhibitors effectively combined with inhibitors of such “vulnerable”
pathways. And, in addition, monotherapies targeting such “vulnerable” pathways
in mTORC1-dependent disease conditions, where markers of mTORC1 pathway
may be used as biomarkers to identify patients who will benefit the most.
1.1.1 Domain structure of mTOR kinase

2

Mammalian target of rapamycin (mTOR) is a Ser/Thr kinase of the
phosphatidylinositol 3-kinase-related kinases (PIKK) family (6, 7). The tertiary
structure

of

mTOR

(Figure1.1a)

comprises—

N

terminal

HEAT

( HEAT (Huntingtin, Elongation factor 3, A subunit of protein phosphatase 2A and
TOR1) repeats, which participate in protein-protein interactions; a FAT (FRAPATM-TRAAP) domain; the FRB (FKBP12-rapamycin-binding) domain; the
Ser/Thr kinase domain, homologous to the phosphatidylinositol 3-kinase (PI3K)
lipid kinase domain; and a FATC (FAT C-Terminal) domain at the C terminus of
the protein (8, 9).
1.1.2 mTOR Complex1 and mTOR Complex2
mTOR forms two distinct multi-protein complexes- mTOR complex 1
(mTORC1), and mTOR complex 2 (mTORC2), which differ in their sensitivity to
rapamycin, subunits, upstream regulatory signals, and downstream functions
(Figure 1.1b) (7, 10).
mTORC1, which is the main focus of this study, has 5 subunits (Figure
1.1b) — (1) mTOR, the catalytic subunit, (2) regulatory-associated protein of
mTOR (Raptor), acts as a scaffold regulates complex assembly and substrate
binding, (3) mammalian lethal with sec-13

mLST8, also GβL, with unknown

function. (4) DEP domain containing mTOR interacting protein (DEPTOR), and
(5) proline-rich Akt substrate 40kDa (PRAS40) both are negative regulators of
mTORC1.

mTORC2 has 6 subunits (Figure 1.1b) —

mTOR, mLST8, and

DEPTOR being the same as in mTORC1. In addition, it has a rapamycininsensitive companion of mTOR (rictor), protein observed with rictor 1 and 2
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(protor 1/2), and mammalian stress-activated map kinase-interacting protein 1
(mSin1) (4, 7).
mTORC1 regulates metabolism, autophagy, cell growth and proliferation
in response to upstream signals, including growth factors, energy, oxygen, stress
and amino acid levels (Figure 1.1b). mTORC2 responds to growth factors.
Downstream functions of mTORC2 include regulation of cytoskeletal organization
and cell survival (Figure 1.1b) (1).

4

Figure 1.1 (a) The domain structure of mTOR. At the N- terminus of mTOR
are:tandem HEAT repeats: anti-parallel α-helices important for protein–protein
interaction; The FAT and FATC domains: modulate the activity of the kinase
domain; The FRB domain: is the docking site of the FKBP12–rapamycin complex
(9). (b) The two mTOR complexes, mTORC1 and mTORC2, their subunit
composition, upstream inputs, downstream functions; and, rapamycin sensitivity
are shown. mTORC1 coordinates cellular growth and proliferation in response to
upstream stimuli, including stress, growth factors, oxygen, energy levels, and
nutrients, via regulating metabolism and autophagy (described in detail in the
text). mTORC2 regulates cell survival and cytoskeleton in response to in
response to growth factors (adapted from (1)).
,

5
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1.1.3 Regulation of mTORC1
mTORC1 activity is regulated by 5 major inputs—growth factors, energy,
oxygen, stress and amino acids (Figure 1.3). In addition recently, activation of
wnt, hippo and notch signaling pathways have been shown to regulate mTORC1
(Figure 1.3) (2, 6).
Most of the upstream inputs to mTORC1 signaling converge at the
heterotrimeric tuberous sclerosis complex (TSC) protein complex, that comprises
TSC1, TSC2 and Tre2–Bub2–Cdc16 (TBC) 1 domain family member 7
(TBC1D7) (Figure 1.2). The TSC2 protein is a GTPase-activating protein (GAP)
specific for Ras homolog enriched in brain (Rheb), which is a ubiquitously
expressed small GTPase of the Ras superfamily, essential for mTORC1
activation (Figure 1.2). TSC1 and TBC1D7 are needed for TSC2 to be fully
active and complex stability. Rheb, in its GTP-bound form (RhebGTP), activates
mTORC1 by direct interaction with the mTOR kinase domain. In the absence of
activating signalling, Rheb is maintained in its GDP-bound state (RhebGDP) by
the TSC that blocks mTORC1 activation (Figure 1.2) (3, 11).
1.1.3.1 Growth factors. The stimulation of tyrosine kinase receptors
(RTKs) or G protein coupled receptors (GPCRs) by a variety of growth factors or
cytokines leads to mTORC1 activation via downstream PI3K-AKT and RasExtracellular signal-regulated kinases (ERK) pathways (Figures. 1.2 and 1.3) (2,
3, 12). Ligand binding activates RTKs, phosphotyrosine residues of RTKs or their
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Figure 1.2 mTORC1 activation by Growth factors and insulin receptors. Growth
factors suppress the TSC1/TSC2 complex function, a negative regulator of
mTORC1, resulting in indirect activation of mTORC1. TSC2 acts as a GAP that
converts active Rheb-GTP to inactive, Rheb-GDP form. Activation of RTKs
activate AKT by PI3K/PDK and mTORC2 mediated phosphorylations. Active AKT
inhibits the TSC1/2 complex by direct phosphorylation of TSC2, and
phosphorylation of PRAS40, mTORC1 suppressor. Also, activation of RTKs
activates MAPK pathway, ERK and RSK phosphorylate TSC2 and inhibit TSC1/2
complex. (adapted from: (3))
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adaptor proteins then recruit PI3K to the plasma membrane via Src Homology 2
(SH2) domains of its regulatory subunit (p85) resulting in activation of the
catalytic p110 subunit of PI3K which, in turn, generates phosphatidylinositol3,4,5-

trisphosphate

(PIP3)

by

phosphorylating

phosphatidylinositol-4,5-

bisphosphate (PIP2). PIP3 then recruits AKT and phosphoinositide-dependent
protein kinase (PDK1) to the plasma membrane via their pleckstrin homology
(PH) domain resulting in phosphorylation at Thr308 and activation of AKT. Full
AKT activation requires mTORC2-dependent phosphorylation at Ser473. The
active AKT phosphorylates TSC2 at specific target sites and inhibits TSCcomplex, leading to mTORC1 activation (Figure 1.3). Also, AKT phosphorylates
proline-rich Akt/PKB substrate 40 kDa (PRAS40) at Thr246 resulting in
dissociation of this inhibitor from mTORC1 (Figure 1.3) (3, 8).
In addition, activation of RTK triggers Ras-GDP/Raf/MEK/ERK cascade.
ERK directly inhibits TSC2 (Figure1.2) as well as activates ribosomal S6 kinase
(RSK) which, in turn, phosphorylates Ser1798 of TSC2 and Ser719, Ser721, and
Ser722 sites of raptor, ultimately resulting in mTORC1 activation (3, 8).
1.1.3.2 Cellular energy status. Low cellular energy levels increases
Adenosine monophosphate (AMP): Adenosine triphosphate (ATP) ratio and also
activates Liver kinase B1 (LKB1), Transforming growth factor β activated kinase1 (TAK1) and Calcium/calmodulin-dependent protein kinase kinase 2 (CaMKK2)
kinases. The various kinases activate AMP-activated protein kinase AMPK via
phosphorylation of Thr172, AMP stabilizes this phosphorylation. Active AMPK
phosphorylates TSC2 and raptor resulting in inactivation of mTORC1 signaling,
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and its downstream energy consuming processes, such as translation, ribosome
biogenesis, etc. (Figure 1.3b) (3, 8).
1.1.3.3 Oxygen levels. Low cellular oxygen or hypoxia downregulates
mTORC1 signaling via various mechanisms. Hypoxia leads to energy stress
which activates AMPK. AMPK can induce regulated in development and DNA
damage responses 1 (REDD1) expression, phosphorylate TSC2 and raptor
resulting in mTORC1 inhibition (Figure 1.3b). Alternatively, hypoxia stabilizes
Hypoxia-Inducible Factor (HIF1α), a transcription factor, induces REDD1
expression which, in turn, competes with 14-3-3 to bind and activate TSC
complex, resulting in mTORC1 inhibition. Moreover, in response to hypoxia
proteins, such as BCL2/adenovirus E1B 19kDa interacting protein 3 (BNIP3) and
promyelocytic (PML) leukaemia prevent Rheb/mTOR interaction, therefore,
inhibits mTORC1 activation (3, 8).
1.1.3.4 DNA damage stress. DNA damage stress induces sestrin 1 and 2
expression, as a part of p53 transcriptional program. Sestrin 1 and 2 activate
AMPK and consequently inhibit mTORC1 (Figure 1.3b) (3, 8).
1.1.3.5 Amino-acids. Amino acids, particularly leucine has been shown to
be essential for mTORC1 activation. Recently, Solute carrier family -7 member
5/-3 member 2 (SLC7A5)/SLC3A2) was shown to regulate export of L-glutamine
in exchange of import of L-leucine into the cells to maintain mTORC1 activity.
The mechanism of amino acid-dependent mTORC1 activation is not clearly
understood. Interestingly studies show that the amino-acid signaling to mTORC1
is independent of TSC-complex, mTORC1 activation in cells deficient in TSC1 or
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TSC2 responded to amino acid deprivation. Recently, Rag family of proteins,
comprising four small GTPases RagA through D which exist as obligatory
heterodimers Rag A/B and Rag C/D, have been shown to regulate mTORC1
activation in an amino-acid dependent manner (Figure1.3c). In the presence of
amino acids active Rag A/B-GTP and Rag C/D-GDP interacts with raptor, leading
to co-localization of mTORC1 to Rab7-rich vesicles, also the site for Rheb,
thereby activating mTORC1. Various studies suggest the involvement of
Mitogen-activated protein kinase3 (MAPK3) and mammalian vacuolar protein
sorting (Vps) 34 homologue (hVps34) in the amino-acid mediated activation of
mTORC1 (3, 8).
1.1.3.6 Non-classical regulatory inputs.
Hippo pathway. The function of the Hippo pathway is to regulate organ
size by maintaining cell number through inhibition of proliferation and activation
of apoptosis. Inhibition of the Hippo pathway kinase large tumour suppressor
homologue (LATS) hypophosphorylates

Yes-associated protein (YAP; also

known as Yorkie homologue), resulting in nuclear translocation of YAP. Nuclear
YAP induces expression of genes associated with proliferation and inhibits the
expression of apoptotic genes.

It was recently shown that YAP positively

regulates mTORC1 and mTORC2. YAP promotes expression of the microRNA
miR-29 which, in turn, inhibits the translation of Phosphatase and tensin homolog
(PTEN) (Figure 1.3 d). PTEN

downregulation activates PI3K pathway and

activates mTORC1 and mTORC2 (2, 13).
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WNT pathway. Glycogen synthase kinase 3β (GSK3β) inhibits mTORC1
by phosphorylation of Ser1379 and Ser1383 of TSC2, resulting in its activation.
WNT signalling inhibits GSK3β and the TSC complex, and thus activates
mTORC1 (Figure 1.3e) (2, 14).
Notch

signaling.

Notch

signalling

regulates

cell

proliferation,

differentiation and development. Notch signalling increases raptor protein
expression and mTORC1 assembly, hence activates mTORC1 (2, 15).
1.1.4 mTORC1 and cell metabolism
mTORC1 is a cell growth and proliferation promoting pathway. It
integrates upstream signals of nutrient availability and cellular homeostasis, as
discussed in the previous section, to promote anabolic processes, including
protein, lipid and nucleotide biosynthesis and inhibit catabolic processes,
including

autophagy

(3,

6).

Recent

global

‘mTOR

omics’

studies—

phosphoproteomics, ribosome profile, transcriptomics and metabolomics, have
been instrumental in the identification of its substrates and target pathways (1619).
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Figure 1.3 Upstream classical and non-classical inputs to mTORC1 are shown.
(a) Growth factor or insulin-like growth factor receptor activates PI3K that forms
PIP3. PIP3 activates PDK and also mTORC2. Both mTORC2 and PDK activate
AKT which, in turn, inhibits TSC-complex, and activates mTORC1. (b) Energy
stress, such as hypoxia and low ATP, and DNA damage stress, both activate
AMPK which activates TSC-complex or inhibits raptor to inhibit mTORC1. (c)
Amino acids recruit mTOR to lysosomes via RAG heterodimers. Rheb activates
mTORC1 at the lysosomes. (d) Inhibition of the Hippo pathway activates
mTORC1 by inhibition of PTEN (e) WNT pathway negatively regulates mTORC1
through inhibition of GSK3β/TSC-complex axis. The model shows elaborate
molecular connections between the above described pathways and mTORC1,
major phosphorylation sites, and their upstream kinases in the signal
transduction (adapted from (2), more details in text).
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1.1.4.1 Protein synthesis. mTORC1 drives protein synthesis (Figure 1.4a).
Infact, the two most well established substrates of mTORC1 are ribosomal S6
kinase (S6K, also called p70S6K) and eIF4E-binding protein (4EBP). mTORC1
phosphorylates S6K Thr389 which, in turn, phosphorylates ribosomal protein S6
(a component of the 40S ribosomal subunit), increases ribosome biogenesis and,
therefore, global protein synthesis. In addition, S6K-mediated

phosphorylation

of eukaryotic translation initiation factor 4B22 (eIF4B22) and eukaryotic
elongation factor 2 kinase (eEF2K), and its direct interaction with eIF3 regulate
global translation through unknown mechanisms.
Also, mTORC1 phosphorylates 4EBP at multiple residues, causes its
dissociation from the eIF4E that allows eIF4G/eIF4E binding at the 5'
oligopyrimidine tract (TOP)- and pyrimidine-rich translational element (PRTE)- of
specific mRNAs to promote translational initiation (2, 20).
1.1.4.2 Glucose metabolism and mitochondrial health. mTORC1 has
been shown to upregulate expression of genes associated with glucose uptake,
glycolysis, and pentose phosphate pathway by inducing translation of HIF1α and,
possibly cellular homolog of the retroviral v-myconcogene (c-Myc) (18, 21), In
addition, mTORC1 has been shown to directly control multiple aspects of
mitochondrial biology, including— biogenesis, quality control, DNA copy number,
gene expression of proteins of oxidative metabolism, membrane potential,
oxygen consumption and ATP levels

16

Figure 1.4 Regulation of metabolism by mTORC1. mTORC1 increases overall
anabolism and inhibits catabolic degradation by autophagy. (a)

mTORC1

stimulates protein synthesis by directly phosphorylating S6K ad 4EBP1.(b)
mTORC1 activates SREBPs, which upregulates gene expression of the key
enzymes of PPP, and lipogenic pathways. In addition, mTORC1 activates CAD
via S6K. (c) mTORC1 inhibits autophagy by targeting ULK1, ATG14, and TFEB
(2).
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in various studies. mTORC1-dependent regulation of PPARγ coactivator-1
(PGC1-α) / yin-yang1 (YY1) interaction controls the transcriptional activity of
PGC1-α that , in turn, has been implicated in regulating mitochondrial biogenesis
and oxidative metabolism (22). In addition, mTORC1 directly interacts with and
phosphorylates B-cell lymphoma-extra large (BCL-xL) resulting in increased
permeability through Voltage-dependent anion-selective channel protein 1
(VDAC1), and mitochondrial oxidative phosphorylation (23). Moreover, mTORC1
regulates mitophagy that plays an important role in maintaining mitochondrial
homeostasis (24).
1.1.4.3 Nucleotide-biosynthesis. mTORC1 stimulates the expression of
5ʹ-phosphoribosyl-1’-pyrophosphate (PRPP, a ribose moiety for nucleotide
synthesis) via the transcription factors sterol regulatory element-binding proteins
(SREBPs). In addition, recently mTORC1 drives de novo pyrimidine biosynthesis
via S6K-mediated phosphorylation of glutamine (Gln)-dependent carbamoylphosphate synthase, aspartate (Asp) carbamoyltransferase, dihydroorotase
(CAD) Ser1859 (Figure 1.4b).
Thus, mTORC1 promotes DNA and RNA synthesis and S phase
progression. Pyrimidine synthesis also drives translation indirectly by increase in
ribosomal RNA and, thus ribosome biogenesis. Purine biosynthesis has not been
directly linked to mTORC1 activation so far. Although increased guanine
synthesis is observed under serum and amino acid fed conditions, the same was
unaffected by acute rapamycin treatment. However, whether mTORC1 regulates
guanine biosynthesis via a rapamycin-independent mechanism remains to be
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investigated. It may be noted that mTORC1 prevents sirtuin 4(SIRT4, a mitochondrial

protein)

mediated

ADP

ribosylation

and

inactivation

of

Glu

dehydrogenase (GDH). Thus, it may lead to higher ATP synthesis via GDH α-ketoglutarate (αKG, a tricarboxylic acid (TCA) cycle intermediate) pathway (2,
17-19).
1.1.4.4 Lipid biosynthesis. mTORC1 increases SREBP-mediated
lipogenic gene expression by S6K-depdendent; and Lipin1, a phosphatidic acid
phosphatase that inhibits SREBP, depdendent, S6K-independent mechanisms
(Figure 1.4b). Increase in lipid biosynthesis produces new membranes and signal
transduction molecules (18).
1.1.5 mTORC1 inhibits autophagy
mTORC1-mediated inhibition is the most well studied regulation
mechanism of autophagy (described in greater detail in section 1.2.2).
1.1.6 mTORC1 in cancer
Impaired mTORC1 signaling, resulting from gain-of-function mutations of
its upstream positive regulators— PI3K, AKT or Ras and/or loss-of-function
mutations of negative regulators— p53, PTEN, LKB1, or TSC1/2, is common in
various human cancers (25). Uncontrolled mTORC1 activation provides a
substantial selective growth and survival advantage to cancer cells. Infact, it
contributes, to varying degrees, to every aspect of tumorigenesis (25).
To cite a few examples, mTORC1 downstream effectors S6K and 4E-BP
selectively promote translation of proteins associated with cell cycle progression
(cyclin-D1) and/or survival (MCL-1) (6, 26). mTORC1 inhibits p27, cyclin-CDK2
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inhibitor (1). mTORC1 inhibits autophagy that is a tumor suppressor pathway. In
addition, mTORC1 activates transcription factors such as HIF1α, SREBP1,
cMYC and PGC1α that favor angiogenesis and enable growth promoting
metabolic adaptation in cancer cells such as increase in glycolysis, the pentose
phosphate pathway and, lipid biosynthesis, mitochondrial homeostasis and
upregulation of gln metabolism (2, 6).
1.1.7 mTOR Inhibitors as anti-cancer therapies
Given the critical importance of this pathway in human tumorigenesis,
there has been tremendous research and clinical interest in mTOR-specific
inhibitors (1).
1.1.7.1 Rapalogs. Rapalogs, also known as the first generation mTORC1
inhibitors, are derivatives of rapamycin. They are allosteric inhibitors of mTORC1
that first bind to FKBP12, and the rapalog-FKBP12 complex then binds the FAT
domain of mTORC1 and inhibits its activity in a kinase- independent manner
(Figure 1.1a) (1, 27).

Rapalogs have been notably successful in otherwise

chemoresistant cancers, particularly renal cell carcinoma and mantle cell
lymphoma, tumors associated with TSC1/2 mutations, and have been relatively
well tolerated in the clinic (27).
However, the success has been limited by modest efficacy in many
tumors, the effect of rapalogs being mostly cytostatic instead of cytotoxic (28).
Among the identified mechanisms associated with reduced efficacy of rapamycin
and its analogs are —the inhibitory effect on certain mTORC1 substrates,
particularly 4E-BP1, is not that durable (29). The rapalogs fail to fully activate
21

autophagy in some cases (30). In addition, active mTORC1 negatively regulates
AKT either directly by activation of growth factor receptor-bound protein 10
(Grb10), which inhibits PI3K, or via S6K mediated inhibition of PI3K or mTORC2.
Thus, mTORC1 inhibition by rapalogs causes feedback activation of PI3K/AKT
and mTORC2/AKT axes (7). Moreover, activation of compensatory pathways
such as MAPK is associated with mTORC1 inhibition (31).
Given the limitations of rapalogs, there has been a lot of interest in the
dual mTORC1/2 kinase inhibitors (TOR-KIs) and PI3K-/TOR – kinase inhibitors,
also referred to as second and third generation mTOR inhibitors (32)
1.1.7.2 mTORC1/2 kinase inhibitors (TOR-KIs). Their mechanism of
action is to competitively displace ATP from the enzyme catalytic site. Rapalogs
cause derepression of mTORC2 by inhibiting S6K –mediated phosphorylation
and inhibition of rictor. mTORC2, in turn, activate AKT by phosphorylating
Ser473 of AKT. Therefore, overcoming mTORC2 dependent PI3K activation. is
one of the most well recognized advantage of TOR-KIs over rapalogs alone.
In addition, they inhibit mTORC1 more effectively. An overall outcome is,
therefore, a more profound effect on almost every cellular aspect compared to
rapalogs (1, 27). Greater and more durable inhibition of 4EBP1 and inhibition of
mTORC2/AKT/glycogen synthase kinase3- β (GSK3-β) and mTORC2/protein
kinase C (PKC) results in an enhanced inhibition of translation (27, 33).
In addition, there is more effective inhibition of glycolysis, as AKTmediated activation of glucose transporter 1 (Glut1), HIF1α and, HIF2α is also
prevented (27, 33). Also, lipogenesis is inhibited by inhibition of ATP citrate lyase
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(ACL), a essential regulator of fatty acid synthesis, and activates GSK3-β
mediated degradation of SREBP1 (27, 34).
There is stronger cell cycle arrest as dual inhibition inhibits translation and
transcription, and promote degradation of cyclins D1 and E, inhibition of
cytoplasmic translocation of p27 causes cyclin-CDK2 inhibition and also
decreases actin stability by inhibiting p27-RhoA binding (27, 35). TOR-KI
inhibitors also induce apoptosis, unlike rapalogs, due to compromised antiapoptotic function of AKT (27, 36).
1.1.7.3 PI3K-mTOR dual kinase inhibitors (PI3K/TOR-KIs). Although
inhibition of mTORC2 by TOR-KI inhibits Ser473 and hence full activation of
AKT, modest, substrate-dependent activity of AKT is still maintained through the
PI3K/ PDK1-mediated phosphorylation of Ser308. This results in compromised
efficacy of TOR-KIs, and at the same time stimulated the interest in dual PI3KmTOR kinase inhibitors.
The advantage of these dual inhibitors is that they inhibit S6K mediated
derepression of AKT phosphorylation at Thr-308 by PI3K/PDK1 axis as well as
AKT-Thr473 phosphorylation by mTORC2/AKT. These PI3K/TOR-KIs are
potentially more effective in the inhibition of tumor growth and survival, given
their multifold ability to target key kinases activating oncogenic pathways,
including lipid and protein biosynthesis, cell cycle and cell growth, survival,
metastasis and angiogenesis (1, 5, 27).
While such strategies are expected to improve the clinical efficacy, given
the overwhelming networking of mTORC1, efforts are needed to develop better
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strategies to effectively exploit this pathway in the clinic. Thus, investigation of
the most “vulnerable" signaling pathway(s) in a given disease setting, not
necessarily upstream or parallel, but also downstream of mTORC1 should be
addressed. The future expects to see in the clinic mTORC1 inhibitors effectively
combined with inhibitors of such “vulnerable” pathways.
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1.2 Overview of autophagy
C de Duve coined the term ‘autophagy’ in 1963, meaning ‘self-eating’ in
Greek, which refers to lysosomal degradation of cytoplasmic content by the cell
(37). There are three types of autophagy: macroautophagy, microautophagy and
chaperone-mediated autophagy (38). This study focuses on macroautophagy,
henceforth referred to as autophagy.
The characteristic feature of autophagy is formation of a doublemembrane structure called autophagosome that sequesters cytoplasmic
components, including proteins, and organelles such as mitochondria, and
targets them for lysosomal degradation (38-40). The process involves a set of
proteins designated as ATG or ‘autophagy-related’ proteins, over 30 of which
have been identified so-far (38, 40). Enormous progress has been made in
understanding the regulatory mechanisms and overall biology of ATG proteins
over the past 30 years, however, there are still questions. For example—
alternative autophagy is known to occur independent of the ‘so-called’ essential
autophagy genes (described in detail in section 1.2.1), including UNC-51-like
kinase 1 (ULK1/2), beclin1 (BECN1), ATG-5,-7, even LC3 (41, 42). Which
compensatory proteins or mechanisms fulfill the job in their absence is not clear?
Further, autophagy is an evolutionary conserved pathway of degradation
and recycling that plays a very important role in maintaining physiological
homeostasis in response to cellular oxygen, nutrient and hormonal demands
(43). Under stress and starvation conditions, levels of autophagy increase,
leading to removal of damaged proteins and organelles, and breakdown of lipids
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and proteins in the process supports cellular metabolism by providing amino
acids, acetyl-CoA and fatty acids (44). In the context of cancer on one hand the
mice lacking ATG4C, ATG5, ATG7 UVRAG, and Bif1, and BECN1 are prone to
tumors (45), on the other hand puncta of key component of autophagosomesLC3 were highly overexpressed almost universally in advanced solid tumor
human specimens (46). Thus, whether to induce or inhibit autophagy in cancers
is an important question in the field.
By management of cellular stress, removal of deleterious cellular
components and maintaining cellular homeostasis, autophagy inherently is an
anticancer pathway. And, prolonged and excessive autophagy can lead to cell
death (47). However, unlike apoptosis and necrosis, autophagy doesnot commit
a cell to death. Due to its reversible nature the highly autophagic cells that
sustain through a stress can quickly degrade autophagic vesicles, and grow
exponentially as soon as the stress is removed. (48). And ultimately hijack
autophagy pathway to support their aberrant cancer metabolism and growth (49).
Thus, depending on the context autophagy can have dual consequences.
The very first results of the clinical trials of inhibitors of autophagy alone and in
combination therapy, in various advanced stage cancers have been published
recently,

and

they

sound

promising

(https://www.landesbioscience.com/journals/autophagy/toc/volume/10/issue/8/).
However, more work is needed in this direction, including—which cancer stage or
type patients and which drug combinations will benefit from induction or inhibition
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of autophagy; development of safer and autophagy specific modulators, etc.
(https://www.landesbioscience.com/journals/autophagy/toc/volume/10/issue/8/).
Thus, the cross-talk between autophagy and cancer cell death and
survival mechanisms is not clear, but there is an intricate connection.
Understanding the precise mechanisms involved in interplay between these
processes will provide exciting opportunities to target cancer and drug
resistance.
1.2.1 The core autophagy molecular machinery
The autophagy pathway comprises 6 different steps, representing different
stages in the formation of autophagosome (Figure 1.5 top). The autophagy
induction signal is followed by the assembly of ATGs at the phagophore
assembly site or omegasomes (in mammals, phosphatidylinositol 3-phosphate
(PI3P)- zinc finger FYVE domain-containing protein 1 (DFCP1) tagged regions
located on the ER membrane). The ATGs, specific soluble N ethylmalemide
sensitive factor attachment protein receptors (SNAREs) and, other tethering
factors then participate in a coordinative fusion of membranes derived from
plasma-membrane, Golgi, and endosomes. This subsequently gives rise to cupshaped initial membrane structure called phagophore that surrounds cytoplasmic
contents to be degraded. Phagophores then expand and ultimately close at their
ends to give rise to double membrane structures called autophagosomes.
Autophagosomes ultimately fuse with the lysosomes and give rise to
autolysosomes, which, along with their contents, are subsequently degraded and
recycled (40).
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Each step is associated with a distinct functional ATG protein complex, as
such six ATG functional units have been described (38, 50) (Figure1.5 bottom).
1.2.1.1 The first step is induction. The most upstream event in
autophagy is activation of the ULK1, a yeast Atg1 homolog, complex (51). The
ULK1 complex consists of ULK1, a Ser/Thr kinase that interacts through its C
terminal domain, with FIP200 (also known as RB1CC1 or ATG17), ATG13L, and
ATG101. These interactions are required for the stability and kinase activity of
ULK1 (51). Activation of the ULK1 complex results in a net dephosphorylation of
this complex, ULK1 autophosphorylation, phosphorylation of ATG13 and FIP200,
and recruitment of ULK1 to the phagophore membrane and autophagy induction
(51).
It is implicated in induction and maturation of the autphagosome. In
addition to its role in the autophagosomal membrane localization of ATG9a (51),
the recent studies have shed light on

some of its downstream substrates,

including—BECN1, AMBRA1, (involved in vesicle nucleation as described
below), and DAPK3 (zipper interacting protein kinase) (52).
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Figure 1.5 Step-wise depiction of autophagy pathway, molecular machinery
involved. Small molecule and genetic modulators of various steps are indicated
with red ovals and blocking arrow towards the step they inhibit. (Top)Various
stages in autophagosome formation are depicted. (Bottom) Molecular Details
associated with each stage of autophagosome formation are shown. (1)Inhibition
of mTORC1 induces induction of autophagy by ULK1 complex activation, (2 and
2’) Nucleation of phagophore requires activation of ULK1 and BECN1/VPS34
complexes. The BECN1/VPS34 complex has three forms, depending on what
are the interacting partners of the core BECN1/VPS34/VPS15- Atg14L and
UVRAG association induce autophagy. In contrast, the Rubicon complex
negatively regulates this complex. (3) Elongation to form complete closed,
souble-membrane membrane structure, autophagosome, requires ATG12-ATG5ATG16 and LC3-PE ubiquitination-like conjugation systems. ATG4 is a protease,
ATG7 is E1-like, ATG3 and ATG10 are E2-like, and ATG12-ATG5-ATG16 is E3like enzyme complex. (4 and 4’)The production of PI3P by the (BECN1-VPS34)
complex recruits phospholipid-binding proteins, including ATG9, ATG2, WIPI1/2
(or ATG18), which function to recruit lipids to the phagophores. (5 and 5’)
Autophagosome fuses with lysosome to form autolysosome, where degradation
takes place. LAMP1/2, Rabs, dynein are needed for the process. (6 and 6’)
Lysosomal hydrolases, Cathepsins -D,-L, and -B hydrolyse the autolysosomal
content, and the products as well as lysosomes are recycled (adapted from (38,
53).
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1.2.1.2 Vesicle nucleation. The membrane
nucleation of autophagosome involves a class III phosphatidylinositol-3-kinase
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(PI3K) complex, also known as the BECN1- vacuolar protein sorting 34 (BECN1VPS34) complex (50). The core BECN1-VPS34 complex comprises VPS34, the
catalytic PI3K; VPS15 (or PIK3R4), a Ser/Thr kinase that regulates the function
of VPS34; and BECN1 (or ATG6), a BH3-domain containing protein that acts as
an adaptor protein (50). Association of additional proteins with these 3 core
protein components regulates the function of this complex (54):
ATG14 is essential for the recruitment of VPS34 to the phagophore,
therefore, the core complex containing ATG14 containing BECN1-VPS34
complex is specific to autophagy(55);
Activating molecule in BECN1-regulated autophagy (AMBRA1) is
involved in nutrient dependent localization of VPS34 to the phagophore (56);
UV Radiation Resistance-Associated Gene (UVRAG) is never found in
vesicles containing ATG14, occurs in late endosomes, therefore, contributes to
formation of autophagosome and maturation by contributing to autophagosomelysosome fusion(55);
Bax-interacting factor 1 (Bif-1) promotes UVRAG binding to the core
complex(57);
RUN
interacting

domain
(Rubicon)

and

cysteine-rich

inhibits

domain

UVRAG-containing

containing,
complexes,

BECN1therefore,

UVRAG/Rubicon containing complexes negatively regulate autophagosome
maturation (58);
BCL-2 family proteins (BCL-2, BCL-xl, MCL-1) inhibit the VPS34BECN1 complex (59).

31

The production of PI3P by the (BECN1-VPS34) complex is critical to
recruit phospholipid-binding proteins, including: (i) Vacuole Membrane Protein 1
(VMP1) and

(ii) ATG9: transmembrane proteins cycling between the

autophagososmes, Golgi and endosomes, and function to recruit lipids to the
phagophores(60);

(iii) WD-repeat-interacting

phosphoinositide

protein

1/2

(WIPI1/2) and ATG2: play a role in recruiting ATG9 from autophagosome to
peripheral mambranes; and (iv) DFCP1: perform an important but yet unknown
function in autophagy (60, 61). Also recently, the PI3P generation was shown to
be critical for the stabilization of ULK1 complex at the omegasome (40).
1.2.1.3 Vesicle expansion and completion. Next, step is the expansion
of the initial membrane structure called phagophore to form a double membrane
vesicle called autophagosome (40). The process involves two ubiquitin-like
conjugation systems— ATG12-ATG5-ATG16L system and the microtubuleassociated protein 1-light chain 3 (LC3 or ATG8) phosphatidylethanolamine (PE)
conjugation system(50, 62-65). ATG12, a ubiquitin-like protein, and ATG5 are
conjugated to each other with the help of ATG7 and ATG10 i.e. an E1-like
activating and an E2-like conjugating enzyme, respectively. ATG12-ATG5 then
bind ATG16L (ATG16-like) that gives rise to a multimeric (ATG12-ATG5ATG16L) complex (50).
LC3 is first processed at its C terminus by ATG4, a cysteine protease, that
exposes its C-terminal glycine residue to form LC3I (66, 67). LC3I is then
converted from unconjugated, cytoplasmic form to PE-conjugated, membrane
bound form called LC3II with the help of ATG7 and ATG3 i.e. an E1-like
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activating and an E2-like conjugating enzyme, respectively(50). ATG12-ATG5ATG16L complex is the E3 ligase for this reaction(68) . As the membrane closes
to

form

complete

autophagosome,

ATG12-ATG5-ATG16L

leave

the

autophagosome and LC3-PE still remains and is needed for the closure of the
autophagosomal membrane(50).
Conversion of unconjugated, cytoplasmic LC3I to PE-conjugated,
membrane (autophagosomes and autolysosomal) bound LC3II is the gold
standard marker of autophagy. By immunofluorescence labeling of endogenous
LC3 or imaging LC3 fused to fluorescent proteins such as GFP, cytoplasmic LC3
appears as diffused form while membrane bound LC3 appears as distict puncta.
By immunoblotting analysis, LC3I appears as a 18 kDa while LC3II appears as a
16 kDa band, the two forms are easily separable using 12-15% SDS-PAGE.
1.2.1.4 Vesicle Maturation (fusion with lysosomes). After completion of
autophagosome formation, autophagosomes fuse with lysosomes to form
autolysosomes. The exact mechanism is unclear, however, the process seems to
depend on several proteins, including — SNAREs, Ras like in rat brain (Rab),
Endosormal sorting complex required for transport (ESCRT), homotypic fusion
and protein sorting (HOPS), LAMP2, LC3-PE, and

the Rubicon- UVRAG

complex (69, 70).
1.2.1.5 Degradation, recycling and termination. Ultimately the cytosolic
contents within autolysosomes are degraded with the help of lysosomal
hydrolases and lipases. LC3II is recycled back to the cytosol by ATG 4 mediated
cleavage of LC3-PE (66).
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Moreover, degradation of autolysosomal contents re-activates mTORC1
which, in turn, terminates autophagy and also leads to formation of protolysosomal tubules and vesicles. Ultimately the lysosomal content of the cell is
restored (71).
Autophagy can be both non-selective leading to bulk disintegration of
cytoplasmic components as well as selective, targeting specific substrates such
as proteins, lipid droplets, and organelles for degradation. For selective
autophagic degradation, targets are tagged with ubiquitin (or other signals, in
case of lipids). The target is then recognized and delivered to autophagosomes
by autophagy cargo receptors such as sequestosome (SQSTM1, also called
p62), Nix, Nuclear Dot Protein 52 (NDP52), and Neighbor of BRCA1 gene
(NBR1) which interact with ubiquitin on target on one side, and with LC3, through
LC3-interaction (LIR) domain on the other side. During autophagic degradation of
the target, the cargo receptors also are degraded, hence p62 degradation is
often used as a marker of autophagic flux (72).
1.2.2 Regulation of Autophagy
Any form of cellular stress, including growth factor, nutrient, oxygen, and
DNA damage, induces autophagy (Figure 1.6). The various mechanisms,
including

regulation

of

autophagy

gene

expression,

post

translational

modifications, important upstream regulatory proteins have been described
below:

34

1.2.2.1 Phosphorylation.
mTORC1. The most widely studied regulator of autophagy is mTORC1.
Under nutrient replete or stress-free conditions, active mTORC1 inhibits
autophagy. mTORC1 regulates autophagy by direct phosphorylation and
inhibition of (52):
(1) the ULK1 complex components—ULK1 (Ser758), ATG13 (site yet to
be determined);
(2) ATG14 (Ser3, Ser223, Thr233, Ser383 and Ser440), an essential
component of autophagic VPS34 kinase complex;
(3) death-associated protein 1 (DAP1, Ser3, and Ser51) that prevents the
activity of ULK1 or VPS34 complexes; and
(4) transcription factor EB (TFEB, that controls genes required for
autophagy and lysosome biogenesis) (Ser142, Ser211) leading to it its
cytoplasmic accumulation, and inhibition of autophagy.
mTORC1 is inhibited in response to starvation of amino acids, growth
factors, nutrients, and DNA damage response which, in turn, results initiation of
autophagy. In general, nutrient starvation in the cells inhibits mTORC1 and
activates autophagy. As autophagy restores nutrients, mTORC1 is reactivated
which, in turn, acts to terminate autophagy. Among the proposed mechanisms,
mTORC1 reactivation initiates generation of tubular proto-lysosomes leading to
reformation of lysosomes which terminates autophagy. In another study, TFEB
is recruited to lysosomes by Rag GTPases where it is phosphorylated by
mTORC1 and results in autophagy inhibition (2).
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Figure 1.6 Networking between cellular stress sensors and autophagy. Three
main stress sensors (indicated in red boxes)- mTORC1, AMPK, ER stress
coordinate protein synthesis in response to cell’s growth factor, oxygen, nutrient,
and genomic homeostasis. Growth factor signaling inhibits autophagy via
RTK/PI3K/AKT/mTORC1 pathway. Energy stress induces autophagy via AMPK,
and via AMPK/mTORC1 pathway. Hypoxia induces autophagy via energy stress
dependent activatation of AMPK or via REDD1/mTORC1 pathwayAmino acid
starvation activates autophagy via RAG/mTORC1 pathway. DNA damage stress
activates induces p53/AMPK dependent autophagy.Finally, ER stress activates
autophagy via IRE1/JNK and PERK/eIF2α pathways. Recently ER stress has
been shown to inhibit mTORC1.
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AMPK. In addition AMPK, which is activated in response to energy
starvation, hypoxia, and DNA damage, also positively regulates ULK-1 complex
by either inhibition of mTORC1 or direct phosphorylation and activation of ULK-1.
Under glucose starvation condition, AMPK was shown to directly phosphorylate
BECN1 and stimulate PI3K complex formation, which promoted autophagy (73).
DAPK/JNK/ERK. In the absence of activating stimuli BECN1 is
sequestered and inhibited by BCL-2 family proteins, such as BCL-2, BCL-Xl,
MCL-1;

14-3-3

or

vimentin,

intermediate

filament

(IF)

protein

(53).

Phosphorylation by tumor suppressor death-associated protein kinase (DAPK) at
Thr119 of BECN1; and/ or by the c-Jun N-terminal kinase (JNK) and ERK of
BCL-2 leads to dissociation of the inhibitory BECN1-BCL-2 complex(74-76).
Subsequently, BECN1 associates with the PI3K complex and promotes
autophagy. Recently, phosphorylation of BECN1 by protein kinase B (PKB) has
been implicated in inhibition of autophagy by promoting BECN1-14-3-3 and
BECN1-Vimentin protein complex formation (77). In addition, BECN1-VPS34
complex activity is regulated by post-translational modifications, including
phosphorylation and ubiquitination (54).
CDK1. Autophagy is suppressed during cell cycle by the cyclin-dependent
kinase-1 (CDK1) mediated direct phosphorylation of VPS34 at Thr159(78).
PKA-, PKC-, CK-. Recently, PKA- or PKC- mediated phosphorylation of
LC3 II was shown to inhibit autophagy by an unknown mechanism(79).
Phosphorylation of p62 at Ser403 by the casein kinase strengthens its binding
with the ubiquitinated targets (80).
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1.2.2.2 Acetylation. ULK1 is activated by acetylation by TIP60 in GSKdependent manner under growth factor deprivation (81, 82). Also, acetylation by
TIP60 is known to stimulate LC3-PE conjugation by increasing ATG3/LC3
binding (83). Moreover, deacetylation of autophagy proteins, ATG12, ATG5,
ATG7 and LC3 by SIRT1 (84) and their acetylation by the p300 acetyltransferase
(85) was shown to regulate autophagy under starvation and nutrient-rich
conditions, respectively.
1.2.2.3 Ubiquitination. Ubiquitination has been implicated in HSP90CDC37 mediated regulation of ULK1 and stabilization of ATG13 by ULKI/2 and
C12orf44 (86, 87). TNF receptor associated factor-6 (TRAF-6) mediated
ubiquitination of BECN1 has been shown to enhance its oligomerization and
promote autophagy. The same study identified deubiquitinating enzyme A20 as a
negative regulator of BECN1 mediated autophagy(88). Overall, the activity of the
core BECN1-VPS34 complex depends on its differential interacting partners
(described in section 1.3.1.2 in more details). These post translational
modifications, in fact, regulate affinity of the various protein partners towards the
core complex and vice versa.
1.2.2.4 Regulation of Gene expression. In addition to TFEB dependent
regulation of autophagy genes, E2Fs-1, -2 and -3 were shown to directly bind
and upregulate the expression of various autophagy genes, including BECN1
(54); (89, 90). NF-kB has also been shown to upregulate BECN1 mRNA levels
and positively regulate autophagy (54, 91). Moreover, miR-30a has been
reported to negatively regulate BECN1 expression (92).
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1.2.3 Autophagy in cancer
Normal cells depend on constitutive autophagy to maintain metabolic
homeostasis and protein and organelle quality control(93). In cancers, depending
on their stage and genetic context, autophagy can have multifunctional effects
i.e. cell death or survival.
1.2.3.1 Autophagy as a tumor suppressor mechanism. In support of a
tumor suppressor role of autophagy, mice deficient in autophagy proteins—
ATG4C, ATG5, ATG7 UVRAG, and Bif1 are prone to tumors (45). Also,
activation of oncogenic pathways such as PI3K/AKT /mTORC1 or onco-proteins
such as BCL-2 causes inhibition of autophagy (52, 53). The proposed
mechanism(s) for the role of autophagy in tumor suppression include (Figure 1.7)
—
Elimination of ROS. Elimination of ROS by clearing impaired mitochondria
(94, 95); by p62 dependent mechanisms of regulation of anti-oxidative gene
expression, including p62/KEAP/NRF2 axis, nuclear factor-κB (NF-κB), and
TRAF-6 complex formation (49, 96, 97).
Anti-inflammatory

mechanism.

Intrinsic

cellular

defense

against

degenerative inflammation, e.g. by inhibition of necrosis, both necroptosis and
PARP- mediated cell death (98). (99-101).
P62 degradation. It allows degradation of p62, and, therefore, inhibits
oncogenic NF-kB, NRF2, and caspase-8 aggregation and activation, thus
preventing inflammation and tissue injury. (101, 102).
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Maintenance of genomic stability. Restrains chromosomal instability and
aneuploidy by mechanisms, including by functioning as a protein and organelle
quality control mechanism, it ensures preventing defacement of cellular proteins
associated with critical cellular processes, including DNA replication, cell division,
DNA repair, etc., and hence occurrence of DNA damage and mutagenesis
ultimately resulting in tumorigenesis (101, 103). In addition, vital cellular
processes, including DNA replication, transcription, mitosis consume energy,
therefore, autophagy functions to ATP availability by maintaining mitochondrial
health (101).
Promotes oncogene induced senescence. Oncogene-induced senescence
In Ras-induced IMR90 senescent fibroblasts autophagy-mediated protein
turnover was shown to be coupled simultaneously to the production of prosenescence cytokines, IL-6, IL-8 (104).
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Figure 1.7 Differential role of autophagy in regulating cell survival in neoplastic
cells versus established tumors. In normal cells, autophagy functions as a cell
intrinsic tumor suppressor mechanism by removal of damaged organelles,
mitigating deleterious ROS, thus limiting chromosomal instability and mutations,
promotes oncogene-induced senescence. In addition, it contributes to effective
immune surveillance, by directly regulating immune cell functions. However,
eventually tumor cells hikack autophagy pathway and use it for their own benefit,
combat metabolic stress, hypoxia, ER stress. Thus, in established tumors it
promotes cancer cell survival.
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1.2.3.2 Prosurvival role of tumor autophagy. In contrast, there is
substantial evidence in support of prosurvival role of tumor autophagy (49, 105).
In a recent investigation using immunohistochemical staining in advanced solid
tumor human specimens, LC3 puncta were moderate to highly overexpressed
almost universally (46). The proposed mechanism(s) for the role of autophagy in
tumor progression (Figure 1.7) —
Autophagy is a robust cellular response to various stresses, including limited
oxygen, nutrient availability, and the endoplasmic reticulum (ER) stress (44),
which facilitates survival during cancer progression in cells with defective
apoptosis (105).
Starvation. The oncogene-induced cancer growth and proliferation poses a
high metabolic and energy demand on the cancer cells, resulting in metabolic
stress(106). Under metabolic stress, autophagy provides for metabolites and
energy by recycling proteins and organelles. Ras activation in cancer cell lines
increases basal autophagy, and causes addiction of cells to autophagy under
starvation conditions and tumor growth (43). ROS signaling is an important
regulator of starvation-induced autophagy (107, 108). In addition, impaired ATP
synthesis activates AMPK which, in turn, activates autophagy(6). Recently, miR376b was shown to regulate starvation-induced autophagy by directly regulating
ATG4C and BECN1 levels (109).
Hypoxia. In addition to starvation, the tumor microenvironment is often
hypoxic which, in turn, favors altered tumor cell metabolism, increased
invasiveness and therapy resistance. Autophagy plays an important role as a

44

cancer cell defense against metabolic stress(110). Hypoxia activates hypoxiainducible factor-1 alpha (HIF-1α, a transcription factor that regulates genes
involved in adaptation to hypoxia) which, in turn, induces the BH3-only protein
Bcl-2/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3) and the related
protein, BNIP3L (111). BNIP3 and BNIP3L induce autophagy by displacing
BECN-1 from the BECN1-BCL-2 complex(112). Activation of AMPK is another
mechanism of autophagy induction that functions independent of HIF-1α (113).
The unfolded protein response (UPR). is another hypoxia-induced signaling
pathway that activates autophagy in an HIF-1-α independent manner. UPR
activates autophagy via—PKR-like ER kinase (PERK)/ eukaryotic initiation factor
2α

(eIF2α)/

activating

transcription

factor

4

(ATF4);

Ire1/TRAF2/JNK;

Ca2+/CaMKK-β/AMPK dependent mechanisms (101).
Taken together, an emerging hypothesis is that in primary cells autophagy
functions as a tumor suppressor process by maintaining mitochondrial function
and combating oxidative stress, mitigating inflammation and counteracting DNA
damage and genetic instability. However, activation of autophagy beyond cellular
threshold can lead to cell death (47). However, unlike apoptosis and necrosis,
autophagy is not always a cell death committed pathway. If a cell lives through
stress, autophagic vesicles are cleared-off, and infact taken-over to support
aberrant cellular growth. Very rightly put in words by the authors, ‘Autophagy,
stress, and cancer metabolism: what doesn't kill you makes you stronger’.
(49).Thus, it promotes cancer cell survival in established tumors by alleviating
stress due to—nutrient starvation, hypoxia, chemotherapy (40, 49).
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1.2.4 Autophagy in anti-cancer therapy
Treatment with anticancer therapies, including targeted cancer therapies
(inhibitors of the PI3K/Akt/mTOR pathway), cytosolic or histone deacetylase
inhibitors (sirtuin-1, HDAC1, HDAC2, and HDAC6), activators of AMPK
(metformin), BH3-mimetics (e.g. ABT-737, obatoclax), DNA damaging agents,
e.g. IR, doxorubicin, etoposide, temozolomide, proapoptotic soluble protein
ligand (TRAIL), imatinib, arsenic trioxide, induce autophagy (114)). Autophagy
induction in response to chemotherapy can have dual consequenses in cancer
treatment, as described below. Consistently, inhibition of autophagy has been
reported to increases as well as decrease cell death in response to anticancer
treatments (114)
1.2.4.1 Autophagy inhibition in anticancer therapy. Autophagy has
been well accepted as a mechanism of drug resistance- in response to
anticancer treatments. It promotes the maintenance of cancer stem cell
compartment or by contributing to recovery of the cancer cells by facilitating
recycling of chemotherapy-induced damaged organelles and protein aggregates,
generation of energy and nutrients to promote rapid proliferation of cancer cells,
and sustains dormancy (47, 115).
Currently there are over 30 clinical trials using autophagy inhibitors, the
first results of 6 of them using HCQ in combination with standard therapies in
multiple aggressive cancers, including — glioblastoma, melanoma, lymphoma
and myeloma, renal and colon cancers were recently released, and show
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potential

safety

and

efficacy

in

this

approach

(https://www.landesbioscience.com/journals/autophagy/toc/volume/10/issue/8/).
Inhibitors of autophagy have been particularly promising in combination
with therapies that are known to stimulate protective autophagy as a side effect.
An interesting example is that of Tyrosine kinase inhibitors (TKIs), e.g. imatinib,
which is the main treatment for chronic myeloid leukemia (CML). The TKIs are
known to induce autophagy, probably through the inhibition of mTORC1 pathway
which, in turn, would confer protective effects on CML stem cells, which leads to
disease relapse following discontinuation of therapy. Pharmacological or genetic
inhibition of autophagy in this case enhanced the efficcacy of imatinib in cell lines
as well as primary CML cells and, resulted in near complete eradication of CML
stem cells(116). Similarly, PI3K/mTOR inhibition using NVP-BEZ235 was shown
to induce apoptosis and protective autophagy in renal cell carcinoma, therefore,
combination of autophagy inhibitors with NVP-BEZ235 led to better efficacy
(117).
1.2.4.2 Autophagy activation as an anticancer therapy. While
substantial evidence exists in support of autophagy as a drug-resistance or a
prosurvival mechanism, contrasting reports show autophagic cell death in
response to cancer therapy. Importantly, Akt/mTORC1 signaling pathway, that is
constitutively active in many cancer cells, is the most well recognized negative
regulator of autophagy suggesting inhibition of autophagy as a potential
tumorigenic mechanism in those cases (7, 77). Additionally fasting, well-known to
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stimulate autophagy, was recently reported to enhance the efficacy of
chemotherapy in animal models (116).
The proposed mechanism(s) underlying autophagy dependent cancer cell
death include, excessive autophagy could be detrimental because of
overcrowding of autophagic vesicles, or extravagant self-destruction by the cells
(118); autophagic cell death has been demonstrated to become active under
oncogenic stress, eg HRAS transformation (119). Also, Aurora kinase inhibition
induces autophagic cell death in Myc transformed cell lines (116). Moreover,
autophagy has been directly regulating stability of tumor suppressor proteins
such as p53. BECN1 was recently shown to enhance p53 stability via USP10
and USP13, two de-ubiquitinating enzymes .Consistently, Beclin1+/− and p53+/−
mice show strikingly similar tumor spectra (120, 121).
Overall while on one hand the results of inhibition of autophagy in clinical
trials show potential in aggressive cancers, the potential in autophagy activation
as an anticancer therapy is also being envisaged. This apparently contradictory
role of autophagy as both a prosurvival and prodeath mechanism reflects
heterogeneity of cancer, and points to the very complexity of the disease. It also
presents an opportunity of feasibility of targeting different, sometimes even
opposite, features of cancer biology.
Notably, given the regulation of multiple cellular aspects by autophagy, the
overall outcome of autophagy activation are bound to be cellular context
dependent. Moreover, the magnitude and length of autophagy stimulation by an
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intervention may give rise to alternative consequences, e.g. Over-induction may
simply eat-up the cell, resulting in cell death.
More detailed studies are required to uncover the complex interactions
between autophagy and other prosurvival, as well as cell-death pathways. The
molecular signature or pathways of contexts, such as metabolic status, specific
oncogenic pathway activation status, etc. associated with cell death or
prosurvival autophagy need to be carefully determined and documented.
1.3 An overview of CLL and Flu resistance mechanisms
Chronic lymphocytic leukemia (CLL) is the most frequent type of leukemia
in the Western world, known to affect mainly elderly individuals (122). However,
about one-third of the patients are below 60 years of age at the time of diagnosis
and, in addition, progressive population obsolescence in many countries
suggests that it could be more frequent in the future (122, 123). The disease is
characterized by an accumulation of CD5/CD19/CD23 + B cells in the peripheral
blood and bone marrow, which are immune-incompetent and neither differentiate
into mature B-cells nor undergo apoptosis(122, 123).
This malignancy has been known to follow a remarkably heterogenous
course in terms of overall survival, symptoms, as well as response to
therapy(123). With the increasing understanding of the disease, the more
aggressive form or short survival times have been more consistently observed in
patients with unmutated V-gene, higher expression of β-2-microglobulin, CD38
and ZAP-70 (and more recently to methylation status of ZAP-70), as well as
aberrations in chromosome 12, 13q14, 14q32, 11q, 17p, and 6q (123). However,
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there are no markers in the field to predict treatment effectiveness, even in the
patients with aggressive form of the disease. Therefore given its complex
biology, CLL is still an incurable disease.
Currently fludarabine (Flu) a purine analog, is used as a frontline therapy
for

CLL

either

alone

or

in

chemoimmunotherapy

combination

with

cyclophosphamide and rituximab (124). Flu is known to induce cell death in both
quiescent and proliferating cells by multiple mechanisms such as incorporation
into DNA, inhibition of DNA/ RNA synthesis and inhibition of DNA repair, etc
(125). Although Flu-based regimens have been greatly successful in improving
the overall outcome in CLL patients, primary or acquired resistance limits the
effictiveness of this therapy especially in the ultra high-risk group Gribben and
O'Brien 2011).
Unfortunately, Flu-refractory patients are resistant to most other
chemotherapies (126). And, the available limited treatment options for such
patients have their own drawbacks, for example alemtuzumab (the anti-CD52
antibody) is associated with either short-term response or no effect in many
patients, flavopiridol (broad cyclin dependent kinase inhibitor) demonstrated
<50% response rates in clinical trials (126). Thus, a detailed mechanistic
understanding of such resistance at the molecular level is urgently needed for the
rational development of appropriate alternative or combination therapies in the
clinic.
According to our current understanding, poor response to Flu has been
associated with biochemical alterations associated with cellular uptake and drug
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metabolism, including those in nucleoside transporters (human concentrative
nucleoside transporter, hCNT3) , deoxycytidine kinase, and 5'-nucleotidase CN-II
activities, activation of DNA repair pathways such as nucleotide excition repair,
deregulated cell cycle checkpoints and defective apoptosis attributed to p53
abnormailities (17p deletion, TP53 mutation) (127) and more recently with
changes in the levels of miRNAs (miR- 34a, miR-21, miR-222, miR-148, etc.)
(128). While p53 defects seem to be central to Flu-refractoriness, current
prognostic models, however, fails to predict therapy response in almost half of
the patients. Predicting non-response is a major focus of current research (129).
Recently, aberrant activation of B-cell receptor (BCR)-associated
signaling pathways, and cues from the microenvironment have been implicated
in B-cell malignancies and their poor response to chemotherapies, including CLL
(130). mTORC1 is a critical component of BCR signaling pathway that integrates
upstream tumorigenic stimuli to downstream growth promoting effector pathways
(131, 132). Inhibition of BCR associated signaling pathways, including mTORC1,
has been identified as a potential target in B cell malignancies, including CLL
(126). Nevertheless, mTORC1 inhibitors failed to induce significant apoptosis of
either cycling or quiescent cells and showed so far modest clinical responses
associated with toxicity (12).
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1.4 Significance and Specific Aims
Fludarabine (Flu), a purine analog, is indicated in the treatment of Chronic
lymphocytic leukemia (CLL), the most common form of leukemia in the Western
world. Although Flu-based regimens have been successful in improving the
overall outcome in patients, primary or acquired resistance is a significant
problem. Inhibition of BCR associated signaling pathways, including mTORC1, is
a potential target in B cell malignancies, including CLL. However, mTORC1
activation status per se has never been studied in the context of CLL or Fluresponsiveness. In addition, allosteric inhibitors of mTORC1 are modestly
effective in the clinic, as they also block feedback inhibition of the upstream PI3K
pathway.
In order to examine the mechanism of acquired resistance against
Flu, Flu-resistant (FluR) B-cell lines derived via chronic exposure of Nalm-6 and
Reh pre B Acute lymphocytic leukemia (ALL) cell lines have been used model
system. The significant findings have been extended to Mec-2 and Mec-1, CLL
derived cell lines, and primary CLL cells.
We show that p-p70S6K (T389), a marker of mTORC1 activation,
predicted Flu response in a panel of cell lines and primary CLL cells, however,
mTORC1 inhibition produced meager cell death and did not enhance the efficacy
of Flu.
In an effort to investigate strategies to effectively exploit mTORC1
addiction in cancers, we hypothesized that ‘Targeting downstream functions of
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mTORC1 will bypass the undesirable feedback signaling events and, therefore,
be more effective than the mTORC1 inhibition itself. To test our hypothesis, we
investigated the following specific aims:
AIMI. To study and target metabolic consequences of mTORC1
activation in FluR cells.
For cancer cells, to sustain tumor growth and survival, an essential
requirement is to maintain nutrient and energy supply. Therefore, activation of
oncogenic pathways, including mTORC1, must induce profound metabolic
dysregulation to meet increased metabolic demand of the growing cancer cells
(16, 133, 134). So, we investigated the metabolic consequences of mTORC1
activation in FluR cells aiming to identify their selective vulnerability to
interference with specific metabolic pathways.
We present data showing that mTORC1 activation leads to metabolic reprogramming in FluR cells that renders them selectively vulnerable to the
inhibition of: oxidative phosphorylation, and pyrimidine biosynthesis (Chapter IV).
This study underscores the importance of selective metabolic dependence of
highly anabolic (FluR cells, with a higher population in S phase) cells, and
suggest that high pyrimidine biosynthesis, and glucose metabolism can be
limiting in the cells with hyperactivated anabolic oncogenic pathways (such as
mTORC1 in FluR cells). We show that targeting de novo pyrimidine biosynthesis
pathway enzymes (by using PALA and leflunomide), or targeting associated
mitochondrial respiration (by rotenone and antimycin) represent effective
strategies to overcome Flu resistance. These data support the hypothesis that
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targeting downstream functions of mTORC1 including, pyrimidine biosynthesis
and glucose metabolism, in rapidly growing cells with deregulated mTORC1
could be an important and effective means to bypass rapalog resistance. On
similar lines, a recent study reported that for cancer cells, which exhibit
dysregulated mTORC1, serum lipids are an important source of unsaturated fatty
acids under low O2 conditions (Young, Regina M et al.,Genes and Dev, 2013).
Ours is the first report showing mTORC1 activation, as measured by pp70S6K (T389), and downstream p-CAD(S1859), as potential biomarkers of Fluresistance in leukemic cells. Our study provides the first evidence for the
relevance of mTORC1-dependent activation of pCAD (S1859) in a disease
setting. An important concern with targeting metabolic pathways could be the
detrimental effects of such an approach on normal tissues. However, the success
of antifolates, L-asparaginase, and other metabolic targets in cancers suggests
that a therapeutic window can be successfully achieved for metabolic pathways
(106). While PALA has been tested in clinical trials (135), leflunomide has been
approved by FDA for rheumatologic diseases (136). In addition, although direct
inhibitors of mitochondrial respiration, including uncouplers, could have obvious
side-effects such as hypothermia. Metformin targets oxidative phosphorylation,
and is one of the most readily prescribed drugs in the world (106).

Thus,

targeting metabolism downstream of mTORC1 activation in cancers can make it
to the clinic in the future.
AIM II To investigate the role of autophagy in regulating cell death or
resistance against Flu.
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For cancer cells an undesirable consequence of their addiction to
metabolic dysregulation is the accumulation of metabolic byproducts (e.g. ROS,
aggregated proteins, and damaged organelles), and rapid exhaustion of cellular
macromolecules(49). Autophagy functions as a prominent cellular recycling
pathway. It allows removal of damaged proteins and organelles, and provides
building blocks for enhanced biosynthesis, thereby acting as a prosurvival
mechanism in this setting(49). Thus, autophagy could be a potential target in
FluR cells under metabolic stress. However, autophagy is known to regulate
variably, i.e. increase or decrease, the efficacy of chemotherapy(69). Therefore,
another important question is to study the regulation of cell death by autophagy
in a given context.
We studied the role and regulation of autophagy in two different settings
— (i) drug inducible autophagy in Flu-sensitive cells and (ii) basal autophagy in
FluR cells, and investigated the underlying mechanism of regulation of
autophagy in these settings.
In FluR cells metabolic stress activates AMPK-dependent, BECN1independent basal autophagy, which contributes to survival of these cells. Using
genetic and pharmacologic inhibitors we show that FluR cells are addicted to
constitutive autophagy for their survival (Chapter III). Increased expression of the
glucose deprivation response network, including unfolded protein response,
autophagy, glucagon signaling, and gluconeogenesis, genes,

has been

described before in the context of acquired resistance to lapatinib in breast
cancer cell lines (137). Similar to our findings in FluR cells, selective targeting of
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autophagy associated with glucose-deprivation could overcome imatinib
resistance (137). Thus, our findings are consistent with the prosurvival role of
autophagy in aggressive forms of cancers (47, 115).
In Flu-sensitive cells, Flu treatment leads to autophagy induction and
increase in autophagic flux. Both pharmacological and genetic means of
inhibition of autophagy, prevented Flu-mediated cell death supporting the
prodeath role of autophagy in response to Flu (Chapter III). While protective
function of autophagy in response to cellular stress is well accepted, the role of
autophagy as a prodeath mechanism is controversial (45, 138). There have been
several reports to show a tumor-suppressive role for autophagy (139). To cite a
few examples, steroid sensitization of dexamethasome resistant cells by
obatoclax is mediated by autophagic cell death (59). In addition, several
oncogenes such as PI3K, AKT, mTOR, BCL-2 family are well established
inhibitors of autophagy and tumor suppressors such as BECN1, PTEN, TSC1,
TSC2, p53 and DAPK are known to activate autophagy (139). Infact, two
transcriptional targets of p53 i.e. Sestrin2 (140) and DRAM (141) have been
shown to induce autophagy mediated cell death. While autophagy has been
described as an alternative form of cell death in the context of defective
apoptosis (142), in our study we found that autophagy contributed to cell death in
apoptosis competent Flu-sensitive cells. Thus, our data qualifies autophagy as
more than a back-up mechanism in the context of Flu-induced cell death.
Further, the antiapoptotic BCL-2 family proteins inhibit both apoptosis and
autophagy, therefore, downregulation of antiapoptotic BCL-2 family proteins and
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enhanced autophagy must coexist in cells dying in response to an apoptosis
inducing therapeutic. However, in the drug-resistant cells that have an increased
dependence on antiapoptotic proteins, whether autophagy is also inhibited
remains unclear. One of the key findings in this report is that MCL-1 plays an
essential role in regulating autophagy and cell death in both Fl-sensitive and Fl-R
cells. Our data underscores the regulation of multiple cell death pathways by
BCL-2 family proteins. FluR cells are a clear example of how important is the role
of BCL-2 family in inhibiting cell death associated with autophagy, in addition to
their anti-apoptotic role. Obatoclax, a pan-BCL-2 family small molecule inhibitor
that binds the BH3 binding domain and inhibits a broad spectrum of antiapoptotic BCL-2 family proteins –effectively induced cell death in FluR cells,
which have no Bim (apoptotic factor), further strengthens this concept. Clearly,
obatoclax is killing FluR cells by releasing BECN-1 from its interaction with MCL1 and other BCL-2 family proteins. Free BECN-1 is then able to induce
autophagy-associated cell death. A previous study in ALL cell lines and primary
cells has shown the heterogeneous and cell type specific induction of a triple
(apoptosis/autophagy/necroptosis) mechanism of cell death even within single
cells by obatoclax (143). They clearly showed plasticity in obatoclax-induced cell
death due to alternative pathway when either apoptosis or autophagy were
inhibited (143). Cell death could be prevented only when both apoptosis and
autophagy were inhibited together while disruption of either of them alone was
ineffective in preventing cell death (143).
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Although Bcl-2 family has been implicated in the regulation of apoptosis in
CLL and of autophagy in other systems (59, 144, 145), ours is the first report
published that demonstrates the role of BCL-2 family in the regulation of
autophagy, in addition to apoptosis, in CLL.
These findings have important implication in designing novel therapeutic
regimens for CLL patients. Although induction of autophagy may be a useful
strategy to induce cell death in Flu-sensitive patients, these findings suggest that
paradoxically, inhibition of autophagy may be a viable treatment strategy for CLL
patients that have demonstrated Flu resistance. Finally from our data it is a
tempting speculation that elevated basal autophagy, as that seen in FluR cells as
well as their response to autophagy inhibition, may be used to predict patient
response to autophagy inhibition. This warrants a more comprehensive analysis
of basal autophagy levels and sensitivity to autophagy inhibition in CLL patients.
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CHAPTER II
Materials and Methods
Reagents, and plasmids. Fludarabine (9-β- D -arabinofuranosyl-2-fluoroadenine
5′-phosphate), chloroquine, 3-methyladenine and compound-C were purchased
from Sigma Aldrich (St. Louis, MO). Everolimus from Selleck (Houston, TX), and
rapamycin (Calbiochem, Billerica, MA). N-phosphonacetyl-L-aspartate (PALA,
NSC224131) was acquired from the NCI/DTP Open Chemical Repository
(http://dtp.cancer.gov) for a study in Dr. Christine McDonald’s laboratory
(Cleveland Clinic). pLKO.1–puro control vector, shATG7 (cat no. SHCLNGNM_006395) and shLAMP2 (cat no. SHCLNG-NM_002294) Mission shRNAs
from Sigma Aldrich (St. Louis, MO) and packaging plasmids pVSVG and dr 8.7
from Invitrogen (Carlsbad,CA). Lentiviral infections were performed using
polybrene (10 μg/ml) from Sigma Aldrich (St. Louis, MO), according to
manufacturer’s instructions. Cells were treated with 10 μM Flu, 25 μM
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chloroquine, 10 mM 3-methyladenine, 10 μM obatoclax (Selleck, Houston, TX)
and 1 μM compound C, and 200 nM everolimus, unless otherwise stated.
Cell lines and patient samples. Human pre-B acute lymphocytic leukemic
Nalm-6, Reh, multiple myeloma RPMI-8226, histiocytic lymphoma U937, and
acute T lymphocytic leukemic Molt-4 cell lines were obtained from the ATCC
(Manassas, VA). Flu-resistant (FluR) cells were generated by initially culturing
cells with a lower concentration (1 μM) of Flu for short periods of time followed by
48 h of recovery time. The drug concentration was increased gradually until the
desired resistance of twice the IC50 value was achieved. The resistant cells were
intermittently treated with verapamil (Sigma Aldrich, St. Louis, MO) to eliminate
the possibility of acquired resistance due to increased expression of efflux
pumps. In addition to derivatized FluR cells, we used Mec-1 and Mec-2 cells (a
gift from Dr. Y. Saunthararajah, Cleveland Clinic), which are CLL-derived cell
lines known to be inherently resistant to Flu (146, 147). Cells were maintained in
RPMI-1640 medium supplemented with 10% fetal bovine serum (Atlanta
Biologicals, Lawrenceville, GA), L-glutamine (Gibco BRL, Gaithersburg, MD), and
antibiotic-antimycotic (Invitrogen, Carlsbad, CA). Cell lines were verified
periodically for morphological characteristics, growth rates, and response to
stimuli using Annexin V/Propidium iodide staining or Trypan blue exclusion.
Passage number was not allowed to exceed 15-20, and cell lines were routinely
tested to be mycoplasma free.
Peripheral blood samples were obtained from patients with CLL after
patients gave informed consent according to protocols approved by the
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Cleveland Clinic institutional review board, according to the Declaration of
Helsinki. Briefly, lymphocytes from blood samples were purified by Ficoll-Paque
PLUS (Amersham Biosciences, Piscataway, NJ) gradient centrifugation. Primary
cells were cultured and cell death was assayed as previously described (148,
149).
Immunoblotting and immunoprecipitation. Cell lysates for immunoblotting and
immunoprecipitation were prepared, as described previously.(150) The primary
antibodies were used against: LC3, pAMPK (Thr172), AMPK, pULK1 (Ser467),
ULK1, cleaved caspase-3, ATG7, p-p70S6K (T389), p70S6K, pCAD (S1859),
cytochrome c, (Cell Signaling Technologies, Danvers, MA); MCL-1, BIM (BDBiosciences, San Jose, CA); NOXA (Enzo Life Sciences, Farmingdale, NY); p62
(Fitzgerald Industries international, Acton, MA ); LAMP2, BCL-2, BCL-XL,
BECN1, BAX (Santa Cruz Biotechnologies, Santa Cruz, CA); BAK (Calbiochem,
Billerica, MA); β-actin (Sigma, St. Louis, MO); PUMA (Prosci Incorporated,
Poway, CA); secondary anti-mouse HRP (Millipore, Danvers, Massachusetts);
and secondary anti-rabbit HRP (Fisher Scientific, Pittsburg, PA).
Confocal immunostaining. Treated cells were washed with PBS and cytoslides
were prepared. The slides were then fixed with 2.0% paraformaldehyde/PBS for
15 min at room temperature, permeabilized with 0.1% Triton X-100 in PBS for 5
min, blocked in 10% fetal bovine serum and 0.1% Triton X-100 in PBS for 1 h
and incubated with the antibodies of interest diluted in blocking buffer for 1 h,
followed by 1 h incubation with fluorescently conjugated secondary antibody, and
finally with 4',6-diamidino-2-phenylindole (DAPI) to stain nuclei. They were then
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mounted in Vectashield (Vector Laboratories, Burlingame, CA). Images were
collected using an HCX Plan Apo 63X/1.4N.A. oil immersion objective lens on a
Leica TCS-SP2 confocal microscope (Leica Microsystems AG, Buffalo
Grove, IL). The average LC3 puncta per cell was determined using Image J
software. For LAMP2/LC3 colocalization, Pearson correlation coefficient was
calculated using Image-Pro Plus software. For all image quantifications, data
were collected from at least 30 cells.
Cell

viability

and

apoptosis

assays.3-(4,5-dimethylthiazol-2-yl)-5-(3-

carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium inner salt(151) (MTS)
assay (Promega, Madison, WI ) was used to assess cell proliferation. Data are
expressed as % reduction in metabolic activity i.e. 100- ((O.D.490nm Untreated)–
(O.D.490nm Treated)] /(O.D.490nm Untreated)*100) versus the indicated
concentrations of the drug. Cell death was measured by trypan blue staining.
Apoptosis was measured using annexin V–fluorescein isothiocyanate and
propidium iodide staining (BD Biosciences, San Jose, CA), as described
previously.(152) Cell death data were acquired on a BD FACS Calibur flow
cytometer (BD Biosciences, San Jose, CA) and analyzed by CellQuest software.
For clonogenic assay, 20 cells/ml were seeded using 30% FBS containing RPMI
media in poly-lysine coated plates, and treated with desired treatments. After 812 days, cells were stained with crystal violet and colonies were scored by an
alpha image analyzer (Alpha Innotech Corp.). The % surviving fraction was then
calculated according to the equation = (number of counts in treated
sample/number of counts in NT sample) × 100. (PMID:18060882). The
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interaction between PALA and Flu in clonogenic assays was determined using
isobolographic method of Chou and Talalay, (PMID:6382953). The combination
index

was

calculated

using

Compusyn

software

(www.combosyn.com),

combination index<1 indicates synergism, fraction affected = (100-%surviving
fraction)/100.
Extracellular flux (XF) analysis. A Seahorse Bioscience XF-24 Flux Analyzer
was used to measure the OCR and ECAR (Seahorse Bioscience, North Billerica,
MA). Cell density titrations were first performed to define the optimal seeding
density for Nalm-6 and Nalm-6-FluR cells. Suspension cells were seeded in
Seahorse Cell-Tak-coated XF 24-well cell culture microplates in 150 μL
Seahorse assay medium [unbuffered DMEM (Sigma D5030), supplemented with
2 mM glutamine, 1mM pyruvate and 11mM glucose] pre-warmed to 37°C. In the
subsequent experiments, Nalm-6 and Nalm-6-FluR cells were seeded in growth
media in plates as described above with 95,000 Nalm-6 cells or 50,000 Nalm-6FluR cells per well to ensure about 90% surface coverage at the time of the
experiment. The cells were incubated for 30 min at 37°C to allow media
temperature and pH to reach equilibrium. During this time, selective metabolic
inhibitors were pre-loaded into injection ports of the cartridge to achieve final
concentrations of 2-DG (100 mM), FCCP (1.5 μM), oligomycin (1.5 μM), rotenone
(0.75 μM), and antimycin A (0.75 μM). Oligomycin and FCCP titrations were
performed for each cell line. Before the first rate measurement, total volume was
adjusted to 500 μL for mito-stress using the Seahorse media and incubated for
an additional 15 min. At the end of incubation, the plate was placed in the
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Seahorse XF24 analyzer. During the assay, baseline rates were measured 3
times. OCR was reported in nmol/min and ECAR in milli-pH (mpH)/min and
further normalized per each cell type. Substrates and selective inhibitors were
injected during the measurements and mixed for 3 to 5 min. OCR and ECAR
were then measured 3 times each.
Cytochrome c release. Cells were washed in 1 x PBS and resuspended in the
lysis buffer (20 mM Hepes, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM
EGTA, 1 mM dithiothreitol, and 250 mM sucrose). To ensure complete cell lysis,
cells were drawn into a 28 1/2 or 30 1/2 -gauge needle using a syringe and then
expelled a minimum of 20 times. Unbroken cells were removed by spinning at
5,000 rpm for 5 min. The supernatant was again centrifuged at 14,000 rpm for 30
min at 4˚C to separate the mitochondrial fraction (pellet) from the cytoplasm
(supernatant). Protein was quantified using Bradford’s method, 5 × SDS sample
buffer was added to the supernatants, and analyzed on 15% SDS-PAGE gels to
probe for cytochrome c release.
ATP quantification. The quantity of ATP was measured using the Mitochondrial
ToxGlo luminescent cell viability assay (Promega, Madison, WI) according to the
manufacturer’s protocol. Briefly, cells were seeded in white 96-well microplates at
1.0 × 104 cells per well in 100 μL growth media, and treated as indicated in
Figure 3 for 2 h at 37ºC, 5% CO2. Then, 100 μL luminogenic ATP detection
reagent was added and luminescence intensity from each well was measured
using a multi-label plate reader (Wallac Victor 1420; Perkin Elmer, Waltham,
MA).
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siRNA transfection. Transfections were performed with control-GFP or S6K1
siRNAQiagen (Valencia, CA, USA) using the Amaxa Nucleofector Kit V (Lonza)
according to the manufacturer's protocol. In brief, (3.0 × 106) cells were
transfected with 500 nM siRNA using program D023.
Statistical analysis. Statistical comparisons between two groups were
conducted by using the Student’s t test and between multiple groups using 2-way
ANOVA with the Prism software (version 5.01). Error bars indicate s.d., which
was calculated from three independent experiments performed in triplicates.
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CHAPTER III
BECN1 and BIM interaction with MCL-1 determine FluDARABINE-resistance
in leukemic B cells
3.1 Introduction
Fludarabine (Flu) is a purine nucleoside analog that is incorporated into
the DNA and which inhibits DNA/ RNA synthesis and DNA repair. Therefore,
apoptosis ultimately occurs in both proliferating and quiescent cells (125). Flu is
an essential component of therapy for chronic lymphocytic leukemia (CLL) (124).
Although Flu-based regimens have been successful in improving the overall
outcome in CLL patients, primary or acquired resistance limits the effectiveness
of this therapy (124). Unfortunately, Flu-refractory patients are resistant to most
other chemotherapies. Thus, a mechanistic understanding of such resistance at
the molecular level is urgently needed for the rational development of appropriate
alternative or combination therapies in the clinic.
The BCL-2 family proteins that regulate apoptotic cell death mediate
chemoresistance in various cancers,(153) including CLL (149, 150, 154). The
anti-apoptotic members of this family, such as BCL-2, BCL-xL, MCL-1, BCL-W,
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and BFL-1 inhibit apoptosis by binding and inhibiting pro-apoptotic BCL-2 family
proteins (155). The pro-apoptotic members include “effector” and “BH3-only”
proteins which, in turn, include “direct activators” and “sensitizers”. Upon
activation the “effector” proteins BAX and BAK oligomerize and form pores on the
outer membrane of mitochondria to release cytochrome c and subsequently lead
to caspase activation and apoptotic cell death (156, 157). Activation of “effector”
proteins requires interaction with the “direct activators”, BIM and BID.
“Sensitizers”, such as PUMA, NOXA, BAD, BIK, BMF interact with and prevent
anti-apoptotic proteins from interacting with BIM and BID (158).
The functionally diverse BCL-2 family proteins,(159) in addition to
inhibition of apoptosis, are known to block autophagy,(54, 160) a catabolic
process regulating cellular turnover in both normal as well as cancer cells. A
double membrane vesicle called an autophagosome initially forms around the
target substrate and later fuses with lysosomes to form autolysosomes, where
degradation takes place.(39, 161) The nucleation of the autophagosomal
membrane is regulated by beclin1 (BECN1, also known as ATG6), a BH3domain containing protein, which forms a class III phosphatidylinositol-3 kinase,
PI3K core-complex consisting of BECN1/Vps34/Vps15 and recruits essential
autophagic proteins to a pre-autophagosomal membrane.(54, 161)The antiapoptotic BCL-2 family proteins, including BCL-2, BCL-xL, and MCL-1 block
autophagy by direct interaction and inhibition of BECN1.(59, 160, 162)
As autophagy can cause both cell death and survival,(163-165) in the
present study, we investigated the molecular alterations of autophagy and BCL-2
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family proteins in response to acquired chemoresistance. By comparing Flusensitive cells and –resistant (FluR) cells that were generated by chronic
exposure to Flu, we delineate how the resistant tumor cells adapt to
chemotherapy by their ability to evade apoptosis by activating autophagy.
Targeting alternative cell survival or cell death pathways could provide attractive
treatment strategies.
3.2 Results
3.2.1 Fludarabine induces autophagy and enhances autophagic flux.
To study the regulation of Flu-induced cell death or acquired resistance by
autophagy, we first examined Flu-induced autophagy in Flu-sensitive cells using
LC3 (also known as ATG8) processing as a marker of autophagy.As there are no
Flu- sensitive CLL cell lines available, we chose pre B leukemic cell lines as a
Flu-sensitive model (IC50 values of ~10 μM), as reported in a previous study to
investigate the autophagic pathway(166). During autophagy, the 18-kDa cytosolic
LC3I is conjugated to phosphatidylethanolamine to form the 16-kDa LC3II, which
associates with the autophagosomal membrane.(161, 167) Flu treatment
increased LC3-II levels, as determined by immunoblotting, in both Nalm-6 and
Reh cells (Figure 3.1a). Consistently, immunostaining analysis for LC3 in Nalm-6
cells treated with Flu for 1 h showed an increase in the number of LC3 puncta,
indicating an enhanced autophagosome formation, p<0.05 (Figure 3.1b and c)
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Figure 3.1 Fludarabine induces autophagy and enhances autophagic outflux.(a)
Western blot for LC-3 I/II expression, with β-actin serving as a loading control, in
Nalm-6 and Reh cells treated with Fludarabine (Flu) for the indicated time. (b)
Representative images of LC3 stained cytospins of Nalm-6 cells treated with Flu
for 1 h. Nuclei were stained with DAPI. Image quantification of LC3 puncta is
shown in (c).(d)Western blot for LC-3 I/II, p62/SQSTM1(p62), and β-actin as a
loading control in Nalm-6 and Reh cells pretreated with chloroquine (CQ) for 1 h
followed by 4 h treatment with Flu. (e) Confocal immunostaing for LC3I/II in
Nalm-6 cells pretreated with CQ for 1 h followed by 4 h treatment with Flu. Nuclei
were stained with DAPI.Quantification of LC3 puncta staining is shown in (f);
*p<0.05, n=3.
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Next, the autophagic flux was examined to distinguish between regulation of
synthesis vs. degradation of LC3I/II (161). To determine autophagic flux due to
Flu, chloroquine (CQ) was used to inhibit degradation through autophagy by
blocking lysosomal acidification (161). CQ pretreatment followed by 4 h Flu
treatment enhanced LC3 processing in both Nalm-6 and Reh (Figure 3.1d), as
well as LC3 puncta in Nalm-6 cells, p<0.05 (Figure 3.1e and f). Additionally, the
levels of p62/SQSTM1 that is degraded by autophagy,(161, 168) decreased after
Flu treatment. Importantly, CQ pretreatment rescued Flu-induced p62/SQSTM1
degradation (Figure 3.1d). Thus, Flu induces autophagy and enhances
autophagic flux in leukemic B cell lines.
3.2.2 Inhibition of autophagy prevents Fludarabine-induced cell death.
Next, we used genetic and pharmacological approaches to inhibit autophagy to
investigate whether autophagy modulated cellular response to Flu treatment.
Short-hairpin (sh) RNA- mediated knockdown of LAMP2, an essential lysosomal
protein required for the late stages of autophagy, i.e. autophagosome to
lysosome fusion(161, 169) prevented basal p62/SQSTM1 degradation in both
Nalm-6 and Reh cells compared to their respective shControl-expressing cells
(Figure 3.2c).
Moreover, Flu-induced cell death was significantly reduced in both shLAMP2expressing Nalm-6 (p<0.001) and Reh (p<0.01) cells compared to their
respective shControl-expressing cells (Figure 3.2a). Similarly, in Nalm-6 cells
expressing shRNA against ATG7 (Figure 3.2d), an essential autophagy protein
that is required for LC3 processing (161, 170), cell death in response to Flu
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decreased significantly (p<0.05) (Figure 3.2b),

Likewise, pharmacological

inhibition of autophagy by 3-methyladenine (3-MA), known to inhibit the class III
PI3K complex required for nucleation of autophagosomes,(161) also significantly
prevented Flu-induced cell death in Nalm-6 cells (p<0.05)

(Figure 3.2e).

Together, these findings suggest that autophagy-associated cell death occurs in
response to Flu treatment in Nalm-6 and Reh cells.
3.2.3 Developing Fludarabine resistance after chronic exposure.
To determine how Flu resistance impacts on the therapeutic response of
leukemic cells, we derived Flu-resistant (FluR) cells. The Nalm-6- and Reh-FluR
cells showed no growth reduction, in contrast to a significant dose-dependent
decrease observed in Nalm-6 (p<0.0001) and Reh (p<0.01) cells, respectively,
following 24 h of Flu treatment (Figure 3.3a). Trypan blue staining showed ~ 50%
cell death in both Nalm-6 (p<0.0001) and Reh (p<0.001) cells compared to <5%
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Figure 3.2 Inhibition of autophagy prevents Fludarabine-induced cell death.(a)
Cell death analysis in shControl and shLamp2-expressing cells in response to 24
h Fludarabine (Flu) treatment as determined by trypan blue staining. (b) Cell
death analysis in shControl and shATG7-expressing cells in response to 24 h Flu
treatment as determined by Annexin V/ PI staining. (c)Immunoblotting for levels
of LAMP2, p62, and β-actin in Nalm-6 and Reh cells expressing shControl or
shLAMP2 lentiviral vectors. (d)Immunoblotting for levels of ATG7, p62, and βactin in Nalm-6 cells expressing shControl or shATG7.(e) Nalm-6 cells were
pretreated with 3-methylalanine (3-MA) for 1 h followed by 24 h Flu treatment
and cell death was determined by Annexin V/ PI staining. All data are expressed
as mean ± s.d. of percentage of cell death; *p<0.05, **p<0.01, ***p<0.001, n=3.
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in the respective FluR cells following 24 h treatment with Flu (Figure 3.3b).
Similarly, AnnexinV/PI-staining showed ~40-50% increase in cell death in Nalm6, but not in the derivative FluR cells with 24 h Flu treatment (p<0.001) (Figure
3.3c). Interestingly, the FluR cells were resistant specifically against Flu. In
contrast, bendamustine, a bifunctional purine analog and alkylating agent
approved by FDA for CLL treatment(124) led to even higher induction of cleaved
caspase-3

(Figure 3.3d) and higher dose dependent increase in growth

reduction (Figure 3.3e) in FluR compared to Nalm-6 cells.
3.2.4 Fludarabine-resistant cells are addicted to basal autophagy.
Next, we compared the levels of autophagy between Flu sensitive and
resistant cells. As found previously, Flu treatment caused an induction of LC3 II
in both Nalm-6 (Figure 3.4a, top) and Reh cells (Figure 3.4a, bottom). However,
in both Nalm-6 and Reh FluR cells, there were higher LC3 II levels in the
untreated cells than in the respective parental cells (Figure 3.4a, top, Figure 3.4a,
bottom), suggesting a higher constitutive autophagy, which did not increase
further with Flu treatment.
To further investigate whether the increase in LC3 II levels in FluR cells
was due to higher basal autophagy or inhibition of flux,(161) we compared the
autophagosome-lysosome fusion between Nalm-6- and Nalm-6-FluR cells
treated with Flu in the presence or absence of CQ, using confocal microscopy.
As demonstrated by co-localization of LC3, a marker for autophagosomes, and
LAMP2, a marker for lysosomes (Figure 3.4b, 3.4c), CQ treatment alone in Nalm6 cells caused an increased number of LC3 puncta,
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Figure 3.3 Developing Fludarabine resistance after chronic exposure.(a) Dose
reponse for the effect of 24 h Fludarabine (Flu) treatment on cell growth in Nalm6, Nalm-6 FluR, Reh, and Reh FluR cells, as determined by the MTS assay.
(b)Cell death analysis in the indicated cell lines in response to 24 h Flu treatment
as determined by trypan blue staining. (c) Cell death analysis in Nalm-6 and
Nalm-6 FluR cells in response to 24 h Flu treatment as determined by Annexin V/
PI staining. All data are expressed as mean ± s.d. of percentage of cell death
from three independent experiments.(d) Western blot analysis for the levels of
cleaved-caspase-3, as well as β-actin as a loading control, in Nalm-6 and Nalm6-FluR cells treated with the indicated concentrations of bendamustine or Flu for
6 h. (e) Dose reponse for the effect of 24 h bendamustime (Bd) treatment on cell
growth in Nalm-6 and Nalm-6 FluR cells, as determined by the MTS assay.
; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, n=3.
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which co-localized with LAMP2 puncta (p<0.0001). Therefore, CQ inhibited
autophagic degradation or flux through lysosomes. Additionally, Flu-treatment
alone of Nalm-6 showed a significant increase in LC3 puncta staining as well as
LAMP2 co-localization compared to untreated Nalm-6 cells (p<0.0001).
Moreover, Flu treatment following CQ pretreatment of Nalm-6 cells greatly
enhanced both LC3 puncta staining as well as co-localization with LAMP2
(p<0.0001), clearly indicating induction as well completion of autophagy. In
untreated FluR cells, there were LC3 puncta, which co-localized with LAMP2 to a
greater extent than in Nalm-6 cells (p<0.001), which were further increased by
CQ treatment (p<0.001), suggesting basal autophagy induction as well ongoing
flux in FluR cells.
Next, we determined the effect of inhibition of autophagy in FluR cells by
depleting cells of LAMP2 using shRNA. LAMP2 expression was significantly
reduced in shLAMP2- compared to that in shControl-expressing FluR cells
(Figure 3.4d). Moreover, cell death was significantly increased (p<0.05) in
shLAMP2-expressing compared to shControl-expressing FluR cells (Figure
3.4e). In addition, inhibition of autophagy by shLAMP2 sensitized FluR cells to
Flu. Similar findings were obtained upon pharmacological inhibition of autophagy
using CQ in FluR cells (Figure 3.4f). These findings were validated in the CLL
derived cell lines Mec-1 and Mec-2. Consistent with previous studies (146, 147),
both of these cell lines were resistant to Flu as no significant decrease in growth
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3.4

Fludarabine-resistant

cells

are

addicted

to

basal

autophagy.(a)Western blot analysis for the levels of LC-3 I/II and β-actin used as
a loading control, in Nalm-6 and Nalm-6 FluR (top) Reh and RehFluR cells
(bottom) in response to Fludarabine (Flu)-treatment for the indicated times.
(b)Nalm-6 and Nalm-6 FluR cells were pre-treated with CQ for 1 h +/- Flu (4 h).
Cells were then fixed, stained with an antibody against LC3 and LAMP2 along
with nuclear staining by DAPI and analyzed by immunofluorescence. (c)
Correlation index for LC3 and Lamp2 in the indicated samples. (d)Cell death
analysis in ShControl and shLamp2-expressing Nalm-6-FluR cells in response to
24 h Flu treatment, as determined by trypan blue staining.(e) Western blot
analysis for the levels of LAMP2 as well as β-actin in Nalm-6-FluR cells
expressing shControl or shLAMP2. (f) Nalm-6 FluR cells were pretreated with CQ
for 1 h followed by 24 h Flu treatment and cell death was determined by Annexin
V/ PI staining. (g) Dose reponse for the effect of 24 h Flu treatment on cell growth
in Mec-2 cells, as determined by the MTS assay. (h) Dose reponse for the effect
of 24 h fludarabine (Fd) treatment on cell growth in Mec-1 and Mec-2 cells, as
determined by the MTS assay. (i) Mec-2 cells were pretreated with CQ for 1 h
followed by 24 h Flu treatment and cell death was determined by Annexin V/ PI
staining. (j) Dose reponse for the effect of 24 h CQ treatment on cell growth in
Mec-1 and Mec-2 cells, as determined by the MTS assay. All data are expressed
as mean ± s.d. of percentage of cell death from three independent experiments;
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, n=3.
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reduction was observed even after treatment with up to 100 µM Flu for 24 h, with
Mec-1 being more resistant (Figure 3.4g and 3.4h). Importantly, CQ pretreatment
sensitized Mec-2 cells towards Flu-induced cell death (p<0.05) (Figure 3.4i). CQ
treatment alone induced cell death in Mec-2 cells (Figure 3.4i) and all of the Fluresistant cell lines we tested. These findings further support that these cells are
addicted to basal autophagy. Interestingly, Mec-1 were more sensitive to CQ
treatment than Mec-2 (Figure 3.4j). This suggests that Mec-1 are more addicted
to constitutive autophagy than Mec-2 cells, the latter also being relatively less
resistant to Flu. Thus, FluR cells become addicted to higher constitutive
autophagy and inhibition of autophagy in FluR cells sensitizes them to Flu
treatment.
3.2.5 Sustained MCL-1 inhibits BECN1-dependent autophagic cell death in
FluR cells.
To distinguish between the opposing roles of autophagy in regulating cell
death, i.e. being pro-death in Flu-sensitive and pro-survival in FluR cells, we next
investigated the relationship between autophagy and apoptosis at the molecular
level. One of the best studied complexes where components of both autophagy
and apoptosis have been known to converge is the multimeric class III PI3K,
BECN1/Vps34/Vps15-complex (59, 160, 162). We first examined the levels of
various BCL-2 family proteins and BECN1 in Flu-treated Nalm-6 and Reh cells
and their resistant derivatives. In both Nalm-6 and Reh cells we observed
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Figure 3.5 Sustained MCL-1 inhibits BECN1-dependent autophagic cell death in
FluR cells. (a)Nalm-6 and Nalm-6 FluR as well as (b) Reh and Reh FluR cells
were treated with Flu (Flu) for the indicated time and 4 h, respectively. Cell
lysates were analyzed by Western blotting for the indicated proteins. β-actin was
used as a loading control. Nalm-6 and Nalm-6 FluR cells were treated with Flu
for 24 h, and (c) MCL-1 immunoprecipitates were analyzed for the presence of
proteins with the corresponding primary antibodies. (d)BCL-2 immunoprecipitates
were analyzed for the presence of proteins with the corresponding primary
antibodies. (e)BCL-xL immunoprecipitates were analyzed for the presence of
proteins with the corresponding primary antibodies. (f) Cell death analysis in
siControl and siBIM-expressing Nalm-6 cells in response to 24 h Flu (Flu)
treatment as determined by trypan blue staining. (g) Immunoblot analysis of BIM
and β-actin as a loading control in Nalm-6 cells expressing siControl or siBIM. (h)
Nalm-6 and Nalm-6 FluR cells were treated with obatoclax for 24 h, and MCL-1
immunoprecipitates were analyzed for the presence of the indicated proteins.
(i)Nalm-6 and Nalm-6 FluR cells were treated with increasing concentrations of
obatoclax (ob) for 24 h and the effect on cell viability was assessed by the MTS
assay.(j) CLL cells were treated with Flu +/- obatoclax (5 µM) for 48 h and cell
death was determined by Annexin V/ PI staining; n=6, *p<0.05, **p<0.01,
***p<0.001 .
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downregulation of MCL-1 within 4 h of Flu treatment. In contrast, MCL-1 levels
were maintained in the resistant derivatives following Flu treatment (Figure 3.5a
and b). Interestingly, BIM levels were greatly reduced and BCL-xL levels were
increased in FluR compared to Flu-sensitive cells. Expression of the other BCL2-family proteins examined was largely unaffected.
Next, we immunoprecipitated MCL-1 from both Nalm-6 and FluR cells
treated with Flu, and examined the levels of associated BECN1 and BIM. In
untreated Nalm-6 cells, both BECN1 and BIM were bound to MCL-1 (Figure
3.5c). Following Flu treatment in Nalm-6 cells there was no BECN-1/MCL-1
complex, as expected due to degradation of MCL-1 following Flu treatment in
these cells. Thus, BECN-1 dissociated and led to the induction of autophagy.
Interestingly, there was much more MCL-1 bound to BECN1 in FluR as
compared to Nalm-6 cells suggesting an inhibition of BECN1-mediated
autophagy in FluR cells. In addition, BIM was released from the MCL-1 complex
following Flu treatment in Nalm-6 cells, therefore, was capable of initiating
apoptosis. Consistent with the very low levels of BIM in FluR cells (Figure 3.5b),
we did not find any BIM in complex with MCL-1 (Figure 3.5c).
Moreover, Flu-induced cell death was significantly reduced in siBIMexpressing compared to siControl-expressing Nalm-6 (p<0.05) cells (Figure 3.5f
and 3.5g). Additionally, we also examined BECN1 and BIM interactions with
BCL-2 and BCL-xL in Nalm-6 and FluR cells treated with Flu (Figure 3.5d and
3.5e). In Nalm-6 cells, none of these interactions changed following Flu treatment
compared to untreated cells. In contrast, in FluR cells, there was enhanced
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interaction of BECN1 with both BCL-2 and BCL-xL compared to that in Nalm-6
cells. These results suggest that BCL-2 family proteins promote cell survival by
inhibition of both apoptosis as well as BECN1-mediated autophagy in FluR cells.
Consistently, treatment with obatoclax, a small-molecule antagonist of the
BH3-binding domain of BCL-2 proteins,caused release of both BIM and BECN1
in Flu-sensitive cells and BECN1 in FluR cells from the MCL-1 complex(Figure
3.5h). Importantly, Nalm-6- and Nalm-6-FluR cells were both sensitive to
obatoclax, validating the importance of functional BCL-2 family proteins in FluR
cells (Figure 3.5i). Moreover, in primary CLL cells 24 h obatoclax treatment
significantly increased (p<0.01) the Annexin V/PI-positive cell population (Figure
3.5j), regardless of Flu sensitivity.
Thus, degradation of MCL-1 following Flu treatment in Flu-sensitive cells
released BECN1 and BIM from the MCL-1 complex and, therefore, autophagy
and apoptosis occurred simultaneously. In contrast in FluR cells, low BIM levels
prevented apoptosis. In addition, BCL-2, BCL-xL, and undegraded MCL-1 kept
BECN1 sequestered and prevented activation of autophagy associated with cell
death. Importantly, inhibition of BCL-2 family using obatoclax could target both
Flu-sensitive cells by induction of BIM-dependent apoptosis and BECN1
dependent autophagy and FluR cells by induction of BECN1 dependent
autophagy.
3.2.6 Basal autophagy in FluR cells is dependent on AMPK but not BECN1.
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Figure 3.6 Basal autophagy in FluR cells is dependent on AMPK but not
BECN1.(a)Immunoblot analysis of LC3, BECN1, p62, and β-actin as a loading
control in Nalm-6 and Nalm-6 FluR cells expressing siControl or siBECN1 treated
with Fludarabine (Flu) for 4 h. (b) a) Cell death analysis in siControl and
siBECN1-expressing cells in response to 24 h Flu (Flu) treatment as determined
by trypan blue staining. (c) Immunoblot analysis of p62 and β-actin as a loading
control in Nalm-6 FluR cells expressing siControl or siBECN1 treated with
obatoclax for 24 h. (d) Cell death analysis in Nalm-6 and FluR Cells in response
to serum starvation for the indicated time, as determined by trypan blue staining,
****p<0.0001, n=3. (e) Nalm-6 and Nalm-6 FluR were treated with Flu (Flu) for
the indicated time. Cell lysates were analyzed by Western blotting for pAMPKThr172, AMPK, pULK-1-Ser467, and ULK-1. (f) Nalm-6 and Nalm-6 FluR, and (g)
Reh cells were treated with Comp C +/- Flu and comp C, respectively, for the
indicated time and analyzed by Western blotting for the levels of pAMPK-Thr172,
AMPK, pULK-1-Ser467, and ULK-1.
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To reconcile our findings of that cell death associated but not basal
autophagy was inhibited in FluR cells, with reports of BECN1-independent
autophagy,(41) we next asked whether basal autophagy
in FluR cells was independent of BECN1. We investigated whether depletion of
BECN1 using siRNA approach affected basal and/ or inducible autophagy in
Nalm-6 and FluR cells. Immunoblot analysis indicated a significant reduction in
BECN1 levels in siBECN1-expressing cells compared to siControl-expressing
Nalm-6 and FluR cells (Figure 3.6a). In siBECN1-expressing Nalm-6 cells LC3
processing by Flu treatment was decreased compared to their respective
siControl-expressing cells (Figure 3.6a),
In addition, the levels of p62/SQSTM1 were higher in both untreated and
Flu-treated Nalm-6 cells suggesting that basal as well as Flu-induced autophagy
is BECN1 dependent in Nalm-6 cells. However, in FluR cells, there was no
change in LC3 processing nor p62/SQSTM1 levels in FluR cells depleted of
BECN1 (Figure 3.6a), further supporting BECN1-independent basal autophagy in
FluR cells.
Further, Flu-induced cell death was significantly reduced in siBECN1expressing Nalm-6 cells (p<0.001) compared to siControl-expressing cells
(Figure 3.6b). This was expected, consistent with what we have shown earlier
(Figure 3.2), Flu induces BECN1 dependent autophagy-associated cell death in
Nalm-6 cells. Interestingly, in FluR cells presence or absence of BECN1 made no
difference to cell survival in response to Flu (Figure 3.6b). These findings further
substantiate that basal autophagy in FluR cells is BECN1 independent, such that
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inhibition of autophagy by LAMP-2 knockdown in these cells causes cell death
(Figure 3.4e) whereas BECN-1 knockdown had no effect on cell viability.
Importantly, obatoclax-induced autophagy was reduced in siBECN1-FluR
compared to that in siControl-FluR cells, as determined by p62/SQSTM1 levels
by Western blotting, supporting the fact that obatoclax relieves MCL-1-mediated
inhibition on BECN1 in FluR cells, thus leading to BECN1 dependent autophagy
(Figure 3.6c).
Under energy stress conditions, the AMP-activated protein kinase
(AMPK) activation

has been

reported to

activate autophagy by direct

phosphorylation of Unc51-like kinase (ULK-1), which forms a multimolecular
complex associated with initiation of autophagy (24). Interestingly, FluR cells
showed increased sensitivity to serum starvation (Figure 3.6d) and higher basal
AMPK and ULK-1 activation and compared to Nalm-6 cells (Figure 3.6e)
suggesting higher metabolic stress in FluR cells. In addition, Flu treatment
caused AMPK and ULK-1 activation in Nalm-6 and Reh cells as determined by
Western blot analysis of pAMPK and pULK-1 (Figure 3.6e and 3.6f), suggesting
that Flu-induced autophagy is mediated by AMPK. Importantly, inhibition of
AMPK in Nalm-6, Reh and FluR cells using compound C (Comp C) inhibited
autophagy, as determined by pULK-1 levels (Figure 3.6 f and 3.6g).
Thus, Flu-induced autophagy was AMPK- and BECN1-dependent in Flusensitive cells. However, basal autophagy in FluR cells, to which they were
addicted as a result of increased metabolic demand, was independent of BECN1
but dependent on AMPK. Taken together, these data establish that autophagy is

89

Figure 3.7 Model for acquired Fludarabine-resistance mechanism.MCL-1
degradation following Fludarabine (Flu) treatment released BIM and BECN1,
leading to apoptosis and cell death-associated autophagy in Flu-sensitive cells.
In FluR cells there was low BIM expression and BECN1 was inhibited by high
MCL-1/BECN1 interaction. FluR cells have a higher metabolic demand, which
activates AMPK-dependent autophagy and promotes survival in these cells.
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critical for regulating cell death and resistance to Flu. Inhibition of BECN1dependent autophagy, reduced

levels of BIM and AMPK-dependent basal

autophagy are key determinants of acquired resistance against Flu (Figure 3.7).
3.3 Discussion
Here we show that autophagy is a critical regulator of cellular response to
Flu in leukemic B cells. Additionally, we show for the first time that Flu-induced
autophagy is BECN1-dependent and is associated with cell death in Flu-sensitive
cells. Autophagy represents an important regulatory mechanism of cellular
response to adverse stimuli. While the protective function of autophagy in
response to cellular stress is well accepted, the role of autophagy as a prodeath
mechanism is controversial.(138, 171)Our data suggest that autophagy
differentially regulates Flu-induced cell death in sensitive cells and those with
acquired Flu resistance. Thus, Flu induces autophagy as well as enhances
autophagic flux in Flu-sensitive leukemic B cells, as previously reported in CLL
cells (172). In Flu-sensitive cells, autophagy contributes to cell death in response
to Flu. Both pharmacological inhibition by 3-MA as well as shRNA-mediated
knockdown of LAMP2 and ATG7 genes that are essential for autophagy
prevented Flu-mediated cell death.
Based on our data on the pro-death function of autophagy in Flu-sensitive
cells, we expected a complete inhibition of autophagy in FluR cells.Surprisingly,
FluR cells showed markers of increased constitutive autophagy: higher LC3 II
expression, LC3 puncta formation, and fusion between autophagosomes and
lysosomes. Additionally, we found that the higher basal autophagy was essential
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for the survival of FluR cells, including the CLL cell lines Mec-1 and Mec-2, as
cell death increased upon autophagy inhibition. These findings indicate that other
adaptive changes might have happened during the chronic exposure to Flu
during selection for Flu resistance, which contributed to overcome cell death
despite increased autophagy.
Importantly, in Flu-sensitive cells MCL-1 degradation following Flutreatment released BECN1 from the MCL-1 complex to cause autophagyassociated cell death. In contrast in FluR cells, MCL-1 levels were sustained,
leading to sequestration of BECN1 and inhibition of BECN1-mediated autophagy
(173). Although the BCL-2 family has been implicated in the regulation of
apoptosis and Flu resistance in CLL, and of autophagy in other systems,(59, 144,
174) to our knowledge this is the first report that demonstrates the role of BCL-2
family in the regulation of autophagy, in addition to apoptosis, in response to Flu,
a prototypical nucleoside analog and DNA damage-inducing therapeutic agent.
The current literature suggests that BCL-2 family members, especially
MCL-1, play an important role in regulating in vitro drug resistance in CLL.(154,
175) Importantly, the BIM-MCL-1 complex has been shown to be critical for
apoptosis modulation in CLL (176). Here, we show that endogenous MCL-1
sequestered BIM in untreated Flu-sensitive cells to inhibit apoptosis. Flu
treatment reduced MCL-1 levels and thus released BIM to initiate apoptosis.
Interestingly, FluR cells had remarkably low BIM levels, which atleast, in part,
were regulated transcriptionally (data not shown). Thus, we show for the first time
that levels of BIM and its interaction with MCL-1 are important determinants of
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Flu-mediated apoptosis. Indeed, we found that the pan-Bcl-2 inhibitor obatoclax
potently induced cell death in both Flu-sensitive and FluR cell lines as well as in
PBMCs

isolated

from

CLL

patients,

as

shown

previously(177).

Importantly,obatoclax treatment induced BIM and BECN1 release from the MCL1 complexes in Flu-sensitive and BECN1 release from MCL-1 in FluR cells in
further support of our interpretation that MCL-1 regulates both apoptosis and cell
death associated with autophagy in response to Flu.
We found that FluR cells exhibit increased sensitivity to serum starvation
compared to Flu-sensitive cells.The increase in metabolic demand may, in part,
explain the increased dependence of FluR cells to basal autophagy. Our data
suggest that basal autophagy in FluR cells, but not in Flu-sensitive cells, was
independent of BECN1. Consistently, we found that siBECN1-expressing Flusensitive cells showed reduced autophagic outflux in the presence of Flu,
whereas siBECN1-expressing FluR cells did not show inhibition of basal
autophagy.
Previous studies have suggested that activation of AMPK, a sensor of the
cellular energy status, stimulates autophagy via AMPK-mediated phosphorylation
of ULK1.(24)Consistent with these findings, we found that AMPK was activated in
response to Flutreatment in Flu-sensitive cells and that AMPK activation was
remarkably higher in FluR compared to Flu-sensitive cells. In addition strong
activation of AMPK corresponded to phosphorylation of ULK-1on Ser467, one of
the AMPK target sites on ULK-1 asreported (24). Moreover, inhibition of AMPK
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prevented ULK-1 activation. Thus, these results suggest that AMPK plays a
critical role in Flu-mediated autophagy.
Flu resistance is often associated with loss of p53.(178) We found that
both Flu and ionizing radiation (IR), a prototypical DNA damaging reagent (152).
induced p53 in Flu sensitive, but not resistant cells (Figure 3.8 a and b). In
addition, p21, a downstream target of p53, was robustly induced by both Flu and
IR in sensitive cells, whereas FluR cells showed only a delayed induction in
response to IR (Figure 3.8 c), suggesting an attenuated p53 function in FluR
cells.
Importantly, any perturbation of p53 pathway — either activation or
inhibition — has been reported to induce autophagy. p53 is known to activate
BECN1-dependent

autophagy

through

JNK-mediated

phosphorylation

of

BCL2.(179) Besides, cytoplasmic p53 is well established to inhibit autophagy
(180). In our preliminary experiments, pifithrin-α, a transcriptional inhibitor of
p53(181), did not affect Flu-mediated autophagy in Nalm-6 cells although p21
upregulation was inhibited (Figure 3.8 d). However, regulation of autophagy by
p53 would require more detailed investigations that are beyond the scope of this
study. Nevertheless, from our data it is conceivable that in FluR cells p53
inactivation may be associated with both inhibition of cytotoxic (BECN1dependent)

and

activation

of

cytoprotective

autophagy

(AMPK/ULK-1-

dependent). Therefore, inhibition of autophagy could possibly be a treatment
strategy for CLL patients with defective p53.
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Figure 3.8 Fludarabine-resistance is associated with p53 inactivation . Western
blot analysis for the levels of p53 and p21 in (a) Nalm-6 versus their derivative
FluR and (b) Reh versus their derivative FluR cells in response to fludarabine
(Flu)-treatment for the indicated time. (c) Western blot analysis for the levels of
p53 and p21 in Nalm-6 versus their derivative FluR in response to 5 Gy ionizing
radiation (IR)-treatment for the indicated time. (d)Western blot for LC-3 I/II, p21 in
Nalm-6 cells pretreated with 10 Μm Pifithrin-α (PFT- α) for 1 h followed by 4 h
treatment with Flu. β-actin was used as a loading control
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In conclusion, our data establish that autophagy can have a differential
outcome on cell death or cell survival.In Flu-sensitive cells, a BECN1-dependent
signaling mechanism mediates autophagic cell death in response to Flu, whereas
FluR cells become addicted to basal autophagy that is required for their cell
survival. This transition is achieved by simultaneous increase in the MCL1/BECN1

interaction

to

inhibit

cell

death-associated

BECN1-dependent

autophagy, as well as activation of BECN1-independent and AMPK-dependent
autophagy. In addition to autophagy, BIM-dependent apoptosis is critical for cell
death due to Flu and FluR cells escape this cell death pathway by regulating BIM
levels. These data suggest that elevated basal autophagy or low BIM levels,
such as that seen in FluR cells may be useful to predict patient response to
chemotherapy and/ or autophagy inhibition. These findings have important
implication in designing novel therapeutic regimens for CLL patients. Although
induction of autophagy may be a useful strategy to induce cell death in Flusensitive patients, these findings suggest that paradoxically, inhibition of
autophagy may be a viable treatment strategy for CLL patients that have
demonstrated Flu resistance.
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CHAPTER IV
Targeting mTORC1-mediated metabolic addiction to overcome
FluDARABINE resistance in malignant
B cells

4.1 Introduction
Fludarabine (Flu; also known as F-ara-A) is a purine analog that is
indicated in the treatment of hematological malignancies, including chronic
lymphocytic leukemia (CLL) (124) and indolent non-Hodgkin lymphomas (182).
Although Flu-based regimens have been successful in improving the outcome in
patients, primary or acquired resistance limits the effectiveness of this therapy
(124).
Recent research in B-cell malignancies, including CLL and non-Hodgkin
lymphomas, suggests that constitutive activation of B-cell receptor-associated
cellular signaling pathways and cues from the microenvironment are the key
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regulators for survival and maintenance of these cancers, as well as their
response to chemotherapy (130). A critical downstream component of the B-cell
receptor signaling pathway is the mammalian target of rapamycin (mTOR) kinase
that is regulated by the phosphatidylinositol 3-kinase (PI3K)/acutely transforming
retrovirus (Akt) pathway (131, 132). The mTOR kinase occurs in two distinct
complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) (7).
Akt activates mTORC1, which in turn phophorylates p70S6 kinase (p70S6K) and
the eukaryotic-initiation-factor 4E-binding protein-1 (4EBP1), whereas mTORC2
phosphorylates and activates Akt (7, 132).
Aberrant activation of mTORC1 occurs in the most common human
cancers, suggesting that mTORC1 signaling confers survival and proliferative
advantages to cancer cells (25). Therefore, allosteric inhibitors of mTORC1,
rapamycin and its analogs (rapalogs) represent an attractive therapy for various
tumors, including hematological malignancies (183, 184). However, these drugs
failed to induce significant apoptosis of either cycling or quiescent cells and
showed modest clinical responses that were also associated with toxicity (184).
The mechanism of resistance to rapalogs is attributed to their ability to inhibit
only one of several downstream targets of PI3K, leaving Akt unaffected.
Moreover, they also disrupt a feedback mechanism that dampens PI3K activity,
leading to a compensatory upregulation of Akt activity, causing counterproductive
prosurvival effects. On the contrary, the ATP-competitive dual PI3K/mTORC1/2
and mTORC1/2 inhibitors display potent anticancer properties both in vitro and in
vivo in a wide range of malignancies, including leukemia (184, 185). Several of
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these compounds are being tested in preclinical models and they show a
consistently robust effect against tumors driven by PI3K/Akt signaling, while they
are ineffective against tumors driven by mutations of Ras, which can signal
through multiple pathways, such as those for MEK and ERK (186)..
An alternative approach for inhibiting mTORC1 is to target its downstream
effectors. A previous study, using unbiased genomic and metabolomic
approaches, reported that gene sets related to specific metabolic pathways,
including the pentose phosphate pathway, fatty acid biosynthesis, glycolysis, and
cholesterol biosynthesis, comprised the top 20 mTORC1-induced genes (18).
mTORC1 stimulates protein synthesis by regulating mRNA translation and
ribosome biogenesis (20). Additional recent reports suggest regulation of
glutamine (187) and pyrimidine metabolism by mTORC1 (17, 19, 188).
Consistently, targeting the enzymes comprising metabolic pathways has been
recently evaluated in various mTORC1-dependent cancer settings (189, 190).
As mTORC1 is associated with poor treatment outcomes in B-cell
malignancies (191), we examined the significance of mTORC1 pathway
activation in Flu-resistant (FluR) cells that were generated by chronic exposure to
Flu. Moreover, we investigated the metabolic consequences of mTORC1
activation in FluR cells, aiming to identify their selective vulnerability to
interference with specific metabolic pathways. Our study reveals mTORC1dependent increase in glycolysis and mitochondrial respiration in FluR cells. In
addition, there was an increase in de novo pyrimidine biosynthesis, which in turn
led to addiction to mitochondrial respiration in FluR cells. We propose targeting
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de novo pyrimidine biosynthesis and mitochondrial respiration as potential
strategies to overcome Flu resistance.

4.2 Results
4.2.1 Fludarabine resistance is associated with hyper mTORC1 activation
Deregulated mTORC1 activity is frequently associated with a variety of
human cancers (25), including leukemia (12, 191) and negatively influences the
response to chemotherapy (191). To determine how mTORC1 regulates Fluresistance, we derived Flu-resistant (FluR) cells from initially sensitive Nalm-6
and

Reh

cells

(148).

Examination

of

phospho-p70S6K

(T389)

using

immunoblotting as an assay of mTORC1 activation status revealed higher
mTORC1 activation in FluR -Nalm-6, -Reh, and CLL derived Mec-2 cell
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Figure 4.1 Fludarabine resistance is associated with mTORC1 activation. (a,b)
Protein expression analysis of p-p70S6K, as a marker of mTORC1 activation in
the indicated cell lines by immunoblot. β-actin was used as a loading control.
IC50, as determined in (c), is indicated at the bottom. (c) Dose response for the
effect of 24 h Fludarabine (Flu) treatment on cell growth in the indicated cell
lines, as determined by the MTS assay. Data are expressed as mean ± SD
(n=3). (d) Protein expression analysis of p-p70S6K and p70S6K in the indicated
primary CLL cells. Numbers indicate CLL patient numbers. FluR, Flu resistant;
FluS, Flu sensitive (e) Effect of 48 h Flu treatment on apoptosis in the indicated
primary CLL cells, as determined by annexin V/PI staining and flow cytometry. %
cell death following Flu treatment was normalized to % cell death in control cells
using the formula: (Livecontrol- LiveFlu/ Livecontrol)*100.
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lines compared to parental Flu-sensitive (FluS) Nalm-6 and Reh cells (Figure
4.1A). We extended our findings to a panel of malignant B lineage cell lines by
comparing Flu-sensitivity (Figure 4.1C), determined by dose-ependent effect of
Flu on MTS reduction, and mTORC1 activation (Figure 4.1B) and found a
remarkably strong correspondence between hyperphosphorylation of p70S6K
and Flu-resistance. In addition, we identified a similar relationship between pp70S6K (Figure 4.1D) and Flu resistance (Figure 4.1E) in primary CLL cells.
Thus, Flu resistance is associated with hyper-mTORC1 activation in B cell
leukemia and lymphoma cell lines.
4.2.2 mTORC1 activation is critical for survival of FluR cells
Next, we studied the effect of mTORC1 inhibition on cell death using two
different rapalogs, rapamycin (Rap) and everolimus (Ev), alone or in combination
with Flu, in FluS versus FluR cells. In Nalm-6, a FluS cell line, 100 nM Rap alone
did not induce apoptosis and, in fact, may have led to reduced cleaved-caspase3 in the presence of Flu (Figure 4.2A). In contrast, in Nalm-6-FluR cells,
mTORC1 inhibition alone did induce cleaved-caspase-3 (Figure 4.2A). However,
Rap (Figure 4.2A) did not sensitize FluR cells to Flu. Rap (100 nM) inhibited
mTORC1 as measured by decreased phosphorylation of p70S6K in FluR cells
(Figure 4.2B). Annexin V/PI staining further confirmed that Rap induced
apoptosis in Nalm-6-FluR, but not in parental FluS Nalm-6 cells (Figure 4.2C).
Similar data were obtained with Ev in Nalm-6 and Nalm-6-FluR cells (Figure
4.2D).
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Figure 4.2. mTORC1 inhibition causes moderate cell death in FluR cells
and does not enhance the cytotoxic efficacy of Flu. (a) Western blot analysis for
cleaved caspase-3 and β-actin, as a loading control, in Nalm-6 and Nalm-6-Fluresistant (Nalm-6-FluR) cells following inhibition of mTORC1 using Rap in
combination with Flu. (b) Nalm-6-FluR cells were treated with the indicated
concentrations of rapamycin (Rap) and cell lysates analyzed by western blotting
for p-p70S6K and p70S6K. (c) Nalm-6 and Nalm-6-FluR cells were treated with
the indicated concentrations of Rap for 48 h and cell death was determined using
annexin V/ PI staining. (d) Nalm-6 and FluR cells were treated with everolimus
(Ev) and analyzed by western blotting for the levels of indicated proteins. β-actin
was used as a loading control. Primary CLL cells were treated with (e) Flu ± Rap
or Rap alone and (f) Flu ± Ev or Ev alone for 48 h and cell death was determined
by annexin V/ PI staining. Data represent mean ± SD (n=7), *p<0.05.
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Importantly, we found similar results in primary CLL cells cultured ex vivo,
indicating that Rap (Figure 4.2E) or Ev (Figure 4.2F) alone induces significant
cell death (p<0.05), but does not enhance sensitivity to Flu, as measured by
annexin V/PI-staining. These findings suggest that even though constitutive
mTORC1 activation is critical for survival of FluR cells, mTORC1 inhibition does
not overcome Flu resistance.
4.2.3 High basal mTORC1 activation leads to higher aerobic glycolysis and
oxygen consumption rates in FluR cells
The efficacy of mTORC1 inhibition is limited by compensatory activation of
oncogenic pathways due to loss of negative feedback on the upstream PI3K/Akt
pathway and by regulation of mTORC1 by other signaling pathways (1, 184,
186). Therefore, we intended to investigate whether targeting downstream
functions of mTORC1 activation was an effective alternative to overcome Flu
resistance. As recent studies suggest that activation of oncogenic pathways,
including mTORC1, must induce metabolic reprogramming in order to provide
ATP and substrates for biosynthesis to support tumor growth (3), we next
investigated whether FluR cells had different metabolic requirements than FluS
cells.
We measured two metabolic parameters: the extracellular acidification rate
(ECAR) and oxygen consumption rate (OCR) using a label-free system with the
Seahorse XF-24 Metabolic Flux Analyzer. ECAR correlates with the rate of
glycolysis because lactic acid is produced from pyruvate generated through
glycolysis, in order to replenish the NAD+ needed for glycolysis. OCR represents
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mainly the mitochondrial respiration rate. We found that Nalm-6-FluR cells had a
significantly higher basal rates of glycolysis (p<0.001; Figure 4.3A) and
mitochondrial respiration (p<0.0001; Figure 4.3B) compared with Nalm-6 cells.
Ev treatment significantly inhibited both ECAR (p<0.02) (Figure 4.3A) and OCR
(p<0.001) (Figure 4.3B) in FluR cells, suggesting that mTORC1 regulates both
glycolysis as well as mitochondrial respiration in FluR cells.
As 2-deoxyglucose (2-DG) is an inhibitor of hexokinase, the first enzyme
required for glycolysis, it also inhibits glycolysis and thus, glucose utilization.
Addition of 2-DG blocked ECAR in both untreated as well as Ev-treated Nalm-6FluR cells (Figure 4.3A), confirming that ECAR was a specific measure of
glycolysis. Moreover, Ev treatment for 16 h had no effect, whereas bendamustine
(Bd), which is known to induce apoptosis in FluR cells (148), led to cytochrome c
release in FluR cells (Figure 4.3C), indicating that the decrease in OCR following
Ev treatment was not an outcome of mitochondrial membrane permeabilization
(156).
We next defined the metabolic profile of Nalm-6 and Nalm-6-FluR cells using
a series of mitochondrial chemical probes (192). Oligomycin blocks ATP
synthesis (and degradation) by the F0 /F1 ATPase, therefore, reducing the OCR in
cells in which oxygen consumption is coupled to ATP synthesis. A decrease in
basal OCR on addition of oligomycin thus provides an estimation of mitochondrial
ATP synthesis. Trifluorocarbonylcyanide phenylhydrazone (FCCP) disrupts the
proton gradient across the inner mitochondrial membrane and therefore
uncouples the electron transport chain from oxidative phosphorylation. As a
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result, the electrons continue to pass through the chain and reduce oxygen to
water, but with no ATP synthesis taking place. As a consequence, mitochondrial
oxygen consumption abruptly increases when FCCP is added to coupled cells.
Moreover, the response to the
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Figure 4. 3. Constitutive mTORC1 activation leads to metabolic re-programming
in FluR cells. Untreated Nalm-6 parental (95,000 cells/well), untreated or 16 h
Ev-treated Nalm-6-FluR (50,000 cells/well) cells were seeded in V7 Seahorse
tissue culture plates. (a) The basal extracellular acidification rate (ECAR) was
calculated for each well for 45 min. In the case of Nalm-6-FluR-untreated and
everolimus (Ev)-treated cells, ECAR was subsequently measured for another 45
min following 100 mM 2-deoxyglucose (2-DG) injection as a control to validate
ECAR as a specific measure of glycolysis. (b) A series of basal oxygenconsumption rates (OCR) were measured for untreated or Ev treated Nalm-6
parental and derivative Nalm-6-FluR cells for the first 45 min and then following
sequential

injection

of

1.5

μM

oligomycin,

1.5

μM

trifluorocarbonyl-

cyanidephenylhydrazone (FCCP), and 0.75 μM rotenone + antimycin A. (c)
Nalm-6 FluR cells were treated as indicated for 16 h. Mitochondria-free cytosol
was then prepared and cytochrome c release was analyzed by western blotting.
(d) Nalm-6 and Nalm-6-FluR cells were plated at 10,000 cells /well in 96-well
plates and treated as indicated for 2 h and ATP was assayed using the
mitochondrial ToxGlo assay from Promega. Data are presented as counts per
second (cps) of luminescence intensity per 10,000 cells. Nalm-6, Nalm-6-FluR,
and Mec-2 cells were: (e) treated with 200 mM 2-DG or cultured in glucose-free
media for 72 h, or (f) treated with 0.75 μM rotenone and antimycin A for the
indicated times and cell death was determined by annexin V/PI staining. Data
represent mean ± SD (n=3), *p<0.05,**p<0.01, ***p<0.001, ****p<0.0001.

112

combination of rotenone and antimycin A, which blocks the respiratory chain at
complexes 1 and 3, respectively, provides a measure of non-mitochondrial
oxygen consumption. The nearly complete inhibition of OCR with rotenone and
antimycin A confirmed that OCR is, indeed, a measure of mitochondrial oxygen
consumption (Figure 4.3B). Oligomycin treatment reduced the OCR, which then
abruptly rose when FCCP was added (Figure 4.3B). These data indicate that
mitochondrial function is not compromised in either Nalm-6 or Nalm-6-FluR cells.
Nevertheless, there was only a low decrease in basal OCR on addition of
oligomycin (<70%) (Figure 4.3B), whereas the maximal OCR achieved using
optimal concentrations of FCCP was close to the basal OCR in both cell lines
(Figure 4.3B). These results suggest that the higher basal OCR in FluR cells was
not coupled to higher ATP synthesis.
Consistently, we found no significant difference in the basal ATP levels
between Nalm-6 and Nalm-6-FluR cells (Figure 4.3D). 2-DG inhibition of
glycolysis significantly decreased ATP levels in Nalm-6 as well as Nalm-6-FluR
cells (p<0.001) (Figure 4.3D), however, the fold decrease in ATP due to 2-DG
treatment, as compared to respective controls, was almost twice as much in the
resistant cells as it was observed in the FluS cells. These results suggest that
glycolysis contributes to ATP synthesis in both cell types. however, FluR cells
depend more than FluS cells on glycolysis. Moreover, both cell types showed a
much greater decrease in ATP levels with inhibition of glycolysis than with
inhibition of the electron transport chain using rotenone and antimycin A (Figure
4.3D), further confirming that oxidative phosphorylation is inefficiently coupled to
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ATP synthesis in these cell lines. Thus, mTORC1 activation led to higher rates of
glycolysis and mitochondrial respiration in FluR cells. Moreover, higher OCR was
not related to higher ATP synthesis in FluR cells.
Consistently, even though 2-DG induced apoptosis in FluS as well as FluR
cells, the Nalm-6-FluR (p<0.05) and Mec-2 FluR (p<0.01) cells were significantly
more sensitive to 2-DG than the FluS Nalm-6 cells (Figure 4.3E). Glucose
deprivation, however, had no effect on survival of Nalm-6-FluR and Mec-2 FluR
cells, but was significantly more toxic to the FluS Nalm-6 cells, p<0.001 (Figure
4.3E). The opposite effects on cell death due to 2-DG and glucose deprivation in
FluS and FluR cells suggest that FluS, but not FluR cells, depended more on
exogenously added glucose for glycolysis.
Interestingly, treatment with antimycin A and rotenone to inhibit mitochondrial
respiration induced significant cell death in a time-dependent manner in Nalm-6FluR [48 h (p<0.01), 72 h (p<0.0001)] and Mec-2 [(48 h (p<0.001), 72 h
(p<0.0001)] cells (Figure 4.3F). In contrast, cell death was negligible in Nalm-6
cells up to 72 h (Figure 4.3F).
Overall, these results indicate that mTORC1 activation leads to higher rates
of glycolysis and mitochondrial respiration in FluR cells, which translated into
higher sensitivity of FluR cells to pharmacological inhibition of glycolysis as well
as mitochondrial respiration. However, the effect of inhibition of mitochondrial
respiration was much more profound in FluR cells, whereas FluS cell survival
depended on glycolysis, and not mitochondrial respiration. Thus, these data
indicate that mitochondrial respiration is a potential target to overcome Flu
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resistance.
4.2.4 FluR cells have higher de novo pyrimidine synthesis
Given our findings that inhibition of mitochondrial respiration was selectively
toxic to FluR compared to FluS cells, and that the higher OCR was not coupled
to higher ATP synthesis in FluR cells, we next investigated potential downstream
effects. The mitochondrial respiratory chain has been shown to be involved in de
novo pyrimidine biosynthesis via the activity of the enzyme dihydroorotate
dehydrogenase (DHODH).(193) mTORC1 promotes glutamine flux through
pyrimidine synthesis via p70S6K, which directly phosphorylates CAD (carbamoylphosphate synthetase 2, aspartate transcarbamoylase, and dihydroorotase) on
Ser-1859, leading to its oligomerization and increased activity (17, 19).
We found higher levels of phosphorylated Ser1859-CAD in FluR than in FluS
cell lines (Figure 4.4A), which corresponded to greater phosphorylated p70S6K
levels (Figure 4.4A). Inhibiting mTORC1 with Ev diminished phosphorylation of
both CAD and p70S6K (Figure 4.4B). Therefore, higher activation of CAD in FluR
cells was indeed an outcome of higher mTORC1 activation. Moreover, PALA [N(phosphonacetyl)-L-aspartate], a pharmacological inhibitor of CAD (194)
synergized with Flu to induce cell death in FluR cells (Figure 4.4C). And,
inhibition of de novo pyrimidine biosynthesis using PALA and leflunomide,
inhibitor of DHODH, decreased the clonogenic
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Figure. 4.4 Constitutive mTORC1 activation activates CAD in FluR cells. (a)
Western blot analysis of Ser1859-CAD and p-P70S6K protein expression in the
indicated cell lines. (b) Nalm-6 and Nalm-6-FluR cells were treated with
everolimus (Ev) for 24 h, and cell lysates were analyzed by western blotting for pp70S6K (T389) and pCAD (S1859). (c) Combination Index- Fraction affected plot
of the effect of combination of Fludarabine (Flu) and N-(phosphonacetyl)-laspartate (PALA) on clonogenic cell survival in Nalm-6-FluR cells. (d) Effect of
PALA and leflunomide treatment on clonogenic cell survival in Nalm-6-FluR cells.
(e) Cell death analysis in siControl and si-p70S6K-expressing Nalm-6-FluR cells
in response to 24 h Flu treatment as determined by annexin V/ PI staining. (f)
Cell cycle distribution in the indicated cell lines was determined by BrdU and 7AAD double staining and FACS analysis. Data represent mean ± SD (n = 3
independent experiments), **p<0.01.

117

survival of FluR cells (Figure 4.4D). To unambiguously define the role of
mTORC1 activation on CAD signaling through p70S6K, we next modulated
p70S6K expression levels. Remarkably p70S6K knockdown by siRNA in FluR
cells caused massive cell death (Figure 4.4E), Increased de novo synthesis of
pyrimidines, as a result of CAD activation, favors progression through S phase of
the cell cycle because of the increased DNA synthesis (195). Consistently, we
found a significantly higher S-phase population in Nalm-6-FluR (p<0.05), Mec-1,
and Mec-2 cells compared to Nalm-6 cells (Figure 4.4F).
Thus, high mTORC1 activation leads to CAD phosphorylation, which
provides a survival advantage to FluR cells. These findings indicate that
mTORC1 activation in FluR cells leads to their selective dependence on
mitochondrial respiration for pyrimidine biosynthesis (Figure 4.5). Importantly, we
show that this specific metabolic dependence of FluR cells can be effectively
exploited by pharmacological inhibition of mitochondrial respiration to induce cell
death in FluR cells.
4.3 Discussion
In this study we establish that mTORC1 activation, as measured by p-p70S6K
T389, defines malignant B-cell response to Flu. This study reveals that mTORC1
activation in FluR cells is associated with specific metabolic adaptation, which
renders these cells highly vulnerable to the inhibition of mitochondrial respiration
and de novo pyrimidine biosynthesis. Aberrant activation of mTORC1 signaling is
a common feature of human cancers,
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Figure. 4.5 Model for targeting metabolic vulnerability of FluR cells. 1.
Hyperactive mTORC1 is associated with Flu-resistance. 2. mTORC1 causes
higher rates of glycolysis, as measured by extracellular acidification rate (ECAR)
and mitochondrial respiration, as measured by oxygen consumption rate (OCR),
both of which are essential for FluR cell survival. Inhibition of mitochondrial
respiration using rotenone and antimycin induces a more dramatic cell death
than inhibition of glycolysis using 2-deoxyglucose, However, the increase in OCR
is not related to ATP synthesis. 3. Infact, constitutive mTORC1 activation causes
CAD S1859 phosphorylation in FluR cells, which leads to de novo pyrimidine
biosynthesis and promotes survival in these cells. As such, FluR cells are also
highly susceptible to inhibition of de novo pyrimidine biosynthesis using PALA
and leflunomide, 4. Dihydroorotate dehydrogenase (DHODH), an essential
enzyme in de novo pyrimidine biosynthesis, requires mitochondrial respiratory
chain electron acceptors to oxidize dihydroorotate (DHO) to orotate, Thus, high
mitochondrial respiration contributes to increase in de novo pyrimidine
biosynthesis, in addition to other functions in FluR cells.
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including hematological malignancies (132, 196). In addition, inhibition of B-cell
receptor-associated signaling pathways, including mTORC1, is a potential
treatment target in B cell malignancies, including CLL (12). p-p70S6K T389
activation status per se has not been previously studied in the context of CLL or
Flu-responsiveness. We show that mTORC1 activation correlates with Flu
resistance in a panel of leukemic cell lines and in primary CLL cells. Despite high
mTORC1 activity in FluR cells, mTORC1 inhibition by rapalogs had limited effect
on cell death, likely due to the previously identified feedback activation of other
oncogenic pathways (27).
To address these limitations, we evaluated an alternative approach by targeting
downstream metabolic reprogramming associated with mTORC1 activation in
FluR cells (18). Consistent with the well-established role of mTORC1 in
regulation of cellular metabolism, our study highlights three important aspects of
metabolic reprogramming in FluR compared to parental Nalm-6 cells. FluR cells
exhibited: (i) accelerated rates of glycolysis and mitochondrial respiration, (ii)
higher de novo pyrimidine biosynthesis, as suggested by hyper-phosphorylation
of CAD, and (iii) cell death in response to inhibition of mitochondrial respiration
and de novo pyrimidine biosynthesis.
An increased rate of glycolysis in the presence of sustained OCR has been
previously reported in leukemic cells, using electrons from non-glucose carbon
sources (197). Glutamine-dependent, glucose-independent Krebs cycle activity
has been also reported in glioblastoma and melanoma cells (197).
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Our data suggest that both FluS and FluR cells utilize glycolysis for ATP
synthesis, therefore, cell death occurs in both cases in response to 2-DG.
However, FluR cells are sensitive to a greater extent to 2-DG, which indicates
that FluR cells are more dependent on glycolysis for ATP synthesis and overall
survival, which, in turn, can be explained by an overall increase in biosynthetic
pathways, such as pyrimidine biosynthesis. Nevertheless, the higher cell death in
Nalm-6 cells than FluR cells in response to glucose starvation seems
contradictory. However, it suggests that the resistant cells have adapted to
survive without exogenous glucose. Thus, Flu-sensitive cells require exogeneous
glucose, and hence they die in response to glucose starvation. In contrast, FluR
cells make their own glucose by activation of endogeneous glucose-deprivation
response pathways, such as autophagy (198) which, therefore, do not die in
response to lack of glucose in the cell culture media.
High glycolysis and intracellular utilization of glucose coexisting with lower
dependence on exogenous glucose due to Increased expression of the glucose
deprivation response network, including unfolded protein response, autophagy,
glucagon signaling, and gluconeogenesis, genes, has been described before in
the context of acquired resistance to lapatinib in breast cancer cell lines (137).
Selective targeting of these pathways associated with glucose-deprivation could
overcome resistance (137). Similarly, we recently reported that FluR cells could
be selectively targeted by inhibition of autophagy (148). Thus, glucose
deprivation response pathways could potentially be targeted to overcome Flu
resistance.
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Treatment with mitochondrial toxins induced robust cell death in FluR cells.
Although we observed higher OCR in FluR than in parental Nalm-6 cells, with
carefully titrated concentrations of FCCP both cell lines demonstrated basal OCR
close to their maximal capacities. Yet, coupling efficiency was low in both cell
lines. Moreover, the two cell lines showed no significant difference in ATP levels.
Overall, these results suggest that the higher OCR in FluR cells was not coupled
to higher ATP synthesis.
Mitochondrial respiration in hematopoietic and various other cell types is known
to be affected by de novo pyrimidine synthesis in a Krebs cycle- and glucoseindependent manner (197). Moreover, mTORC1 activation was recently shown to
enhance glutamine flux through pyrimidine biosynthesis (17, 124) and
leflunomide was reported to overcome Flu resistance in CLL (199). Consistent
with those data, we found higher pCAD (S1859) levels in FluR cells. Moreover,
inhibition of pyrimidine biosynthesis using two different inhibitors, PALA and
leflunomide, reduced clonogenic survival of FluR cells. Importantly, PALA acted
synergistically with Flu in inducing cell death in FluR cells. These findings
conclusively establish that constitutive mTORC1 activation promotes de novo
pyrimidine synthesis in FluR cells, to which they are addicted.
Notably, p70S6K knockdown induced remarkable cell death in FluR cells
compared

to

FluS

cells.

This

further

supports

the

importance

of

mTORC1/p70S6K/CAD axis in regulating pyrimidine biosynthesis and, therefore,
survival in FluR cells. The fact that rapalog treatment, despite reducing active
p70S6K levels more effectively than S6K knockdown, was less effective in
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inducing cell death, seems intriguing. However, rapalog treatment will also affect
other targets of mTORC1 which, in turn, may be associated with pro-survival
pathways (1). For example, mTORC1 inhibition activates the ULK-1 (ATG1)
complex which, in turn, will activate autophagy, which is indeed a well
established pro-survival pathway (200). Consistently, we have previously
reported that FluR cells depend on autophagy for their survival (148). Therefore,
these findings further underscore the importance of targeting downstream
pathways in mTORC1-dependent cancers.
We recognize that OxPhos inhibition may cause cell death due to multiple
reasons, e.g. inhibition of recycling of NAD+ (201), inhibition of de novo
pyrimidine biosynthesis (202), ROS(203) and, disruption of MMP leading to
Bax/Bak oligomerisation (197). Nevertheless, our data suggest that one of the
reasons should be de novo pyrimidine biosynthesis given high proportion of Sphase cells and high pCAD S1859. The DHODH enzyme, a critical component of
this pathway, is located in the inner mitochondrial membrane and must use
mitochondrial electron transfer chain (ETC) components, i.e. ubiqinone as the
proximal acceptor and coenzyme q as the ultimate electron acceptor, in order to
carry out oxidation of DHO to orotate.
In summary, we established mTORC1 activation, as measured by p-p70S6K
T389, and downstream pCAD S1859 as potential biomarkers of Flu-resistance in
leukemic cells (Figure 4.5). FluR cells depend on mTORC1-dependent de novo
pyrimidine biosynthesis and mitochondrial respiration for survival. Thus, directly
targeting de novo pyrimidine biosynthesis pathway enzymes using PALA and
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leflunomide, or targeting mitochondrial respiration represent effective strategies
to overcome Flu resistance.
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CHAPTER V
SUMMARY AND CONCLUSIONS
5.1 Summary of major findings
The present work has focused on investigating mTORC1 pathway as a
potential target in FluR cells. Given the limited effectiveness of rapalogs due to
activation

of

prosurvival

pathways,

we

investigated

whether

targeting

downstream functions of mTORC1 was more effective than rapalogs in inducing
cell death in mTORC1-dependent cancer cells,
Since oncogenic activation Is associated with metabolic reprogramming to
promote tumor growth, we explored activation and the possibility of targeting
downstream metabolic consequences of mTORC1 activation in FluR cells.
Secondly, autophagy, an important consequence of mTORC1, plays an
important role in chemoresistance. However, autophagy can increase or
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decrease cell death in response to chemotherapy, We investigated the role of
autophagy in regulating cell death and resistance in the context of Flu.
Key research findings include (Figure 5.1):
1. In Flu-sensitive cells, Flu-induced cell death associated BECN1dependent autophagy.
2. MCL-1 degradation following Flu treatment released BIM and BECN1,
leading to apoptosis and cell death-associated autophagy in Flu-sensitive
cells. In FluR cells there was low BIM expression and BECN1 was
inhibited by high MCL-1/BECN1 interaction.
3. p-p70S6K (T389), a marker of mTORC1 activation, predicted Flu
response in a panel of cell lines and primary CLL cells, however,
mTORC1 inhibition produced meager cell death and did not enhance the
efficacy of Flu.
4. mTORC1 causes higher rates of glycolysis, as measured by ECAR and
mitochondrial respiration, as measured by OCR, both of which are
essential for FluR cell survival.
5. Inhibition of mitochondrial respiration using rotenone and antimycin
induces a more dramatic cell death than inhibition of glycolysis using 2deoxyglucose, However, the increase in OCR is not related to ATP
synthesis.
6. Constitutive mTORC1 activation causes CAD S1859 phosphorylation in
FluR cells, which leads to de novo pyrimidine biosynthesis and promotes
survival in these cells. As such, FluR cells are also highly susceptible to
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inhibition of de novo pyrimidine biosynthesis using PALA and leflunomide,
Thus, high mitochondrial respiration contributes to increase in de novo
pyrimidine biosynthesis, in addition to other functions in FluR cells.
7. FluR cells have a higher metabolic demand, which activates AMPKdependent, and BECN1-independent autophagy and promotes survival in
these cells.
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Figure 5.1 A schematic diagram illustrating that both mTORC1 and BECN1independent autophagy are critical determinants of survival in FluR cells. (a)
MCL-1 degradation following Flu treatment freed the pro-apoptotic (b) BIM and
(c) the key mediator of autophagy, BECN1, leading to cell death-associated
autophagy in Flu-sensitive cells(148). (d) Low BIM expression and (e) BECN1
sequestration by sustained MCL-1 prevented cell death in FluR cells. (f)
mTORC1 activation in FluR cells causes (1) increased levels and dependence on
glycolysis and (2) mitochondrial respiration, and (3) CAD phosphorylation that
leads to de novo pyrimidine biosynthesis. (g) This metabolic adaptation provides
survival

advantage

to

FluR

cells.

(h)

mTORC1–dependent

metabolic

reprogramming also renders FluR cells addicted to AMPK-dependent, BECN1independent autophagy ( Sharma, Janocha et al. in revision, 148).
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5.2 Conclusions
To conclude, our studies address clinically relevant question in mTOC1
biology. We show that targeting downstream consequence of mTORC1
activation, de novo pyrimidine biosynthesis and oxidative phosphorylation in FluR
cells is indeed an effective mechanism to overcome resistance, compared to
targeting mTORC1 itself (Figure. 5.1).
Further, our findings contribute towards addressing a long standing
question of context-dependent, prodeath versus prosurvival, function of
autophagy (Figure. 5.1). Flu treatment induces BECN1-dependent autophagic
cell death in FluS cells, whereas FluR cells that are under metabolic stress are
dependent on basal AMPK-dependent BECN1-independent autophagy. We
propose, upstream stimuli (overstimulation by chemotherapy treatment versus
stimulation by metabolic stress within cellular threshold limits), and molecular
regulatory inputs (BECN1-dependent versus AMPK-dependent) could be
determining factors for prodeath versus prosurvival function of autophagy.
In the future studies, the molecular mechanisms connecting the various
pathways that have been identified in this work, as contributing to Flu-resistance
should be addressed.
Some of the important questions, include— What is the mechanism of
mTORC1 activation in FluR cells? How autophagy and mTORC1 both can be
active in FluR cells? Whether basal autophagy in FluR cells contributes to the
rapalog resistance observed? What is the exact contribution of autophagy in
terms of surviving metabolic stress in FluR cells?
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What is the mechanism of

BECN1-independent autophagy? What is the mechanism by which mTORC1
upregulates glucose metabolism? What advantage this selective metabolic
adaptation (high OCR, ECAR, high pyrimidine biosynthesis) offers to FluR cells?
What other pathways mTORC1 targets? Last, but not the least understanding
magnitude and nature of upstream stimuli; identification of specific molecular
mechanisms associated with different outcomes of autophagy observed in FluR
versus Flu-sensitive cells are warranted.
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CHAPTER VI
FUTURE DIRECTIONS
UNCOUPLING OF mTORC1 ACTIVATION AND AMPK-DEPENDENT
AUTOPHAGY IN FLUDARABINE RESISTANT LEUKEMIC CELLS

6.1 Mechanism of mTORC1 activation in FluR cells
We show using various markers, including p-p70S6K T389, p-PS6K
235/236, and pmTOR 2481 (Figure 6.1 a and Chapter IV) that Flu- resistance is
associated with hyperactivation of mTORC1 pathway, mTORC1 regulates cell
growth in response to five major signals – growth factors, energy status, oxygen,
and amino acids (discussed in chapter1).
The TSC complex is the central node that delivers regulatory inputs from
various upstream pathways (discussed in chapter 1). We did not find any
significant differences in TSC complex components between Nalm-6 FluS and FluR cells (Figure.6.1b).
Growth factor pathway dependent regulation. The levels of pAkt S473, a
marker of PI3K pathway, and Erk1/2 T202/Y204, a marker of MAPK pathway
activation, were higher in FluR than FluS cells (Figure 6.1b), suggesting the
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growth factor signaling pathway activation upstream of mTORC1 activation.
Further CAL 101 (a PI3K delta isoform inhibitor), diminishes constitutive Akt and
mTORC1 activation in Mec-2 cells (Figure 6.1c).
Growth factor pathway activation (discussed in chapter 1) may be further
investigated in the future, including the TSC complex (phosphorylation status of
particularly Akt/PKB-target sites, i.e. S939, Y1571, and T1462, and Erk target
sites, including S540 and S664. Akt is also known to increase mTORC1
activation by promoting PRAS40 dissociation from the mTORC1 complex.
Therefore, mTORC1 complex formation may be investigated.
Energy stress. Energy stress activates AMPK, which inhibits mTORC1
either by direct phosphorylation of mTORC1 or activation of TSC, an upstream
inhibitor of mTORC1 pathway, leading to induction of autophagy (discussed in
chapter 1). We observed co-existence of AMPK and mTORC1 activation in FluR
cells (Chapter III, and Figure 6.1b), which is contradictory to the well established
role of AMPK to inhibit mTORC1.

Such uncoupling between mTORC1 and

AMPK has never been reported before, and will be, therefore, interesting to
investigate further.
Amino acids. Interestingly, amino acids provide an essential signal that
positively regulates mTORC1. The activation of mTORC1 by amino acids is
known to be independent of TSC1/2, because the mTORC1 pathway remains
sensitive to amino acid deprivation in cells that lack TSC1 or TSC2 (Nobukuni et
al., 2005). In addition, the RAG GTPases recruit mTORC1 to lysosomes, where
RHEB activates it (204). p62 is known to directly associate with active RAGs
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Figure. 6.1 FluR cells have constitutive activation of mTORC1 which is critical for
their survival. Nalm-6 and Nalm-6-FluR cells were treated with everolimus (Ev)
for 24 h and (a) protein expression analysis of various markers of mTORC1
activation was performed. (b) protein expression analysis of various upstream
regulators of mTORC1 activation was performed. (c) Mec-2 cells were treated
with the indicated concentrations of CAL-101 for 24 h. and lysates were analyzed
for the indicated proteins.
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and mTORC1 via Raptor (205). Our preliminary data indicate that: (i) p62 levels
and its co-localization with mTORC1 are higher in FluR than parental Nalm-6
cells (Figure 6.2a and b), and (ii) ectopic expression of p62 is protective against
Flu in Nalm-6 cells (Figure 6.2c and d), suggesting that p62/RAG GTPases/Rheb
may be implicated in mTORC1 activation.
Given that mTORC1 is regulated by various upstream pathways, however,
the presence of amino acids has been shown to be essential for activation of the
mTORC1 kinase. Our hypothesis is that energy stress-dependent regulation of
autophagy in FluR cells occurs independent of mTORC1 inhibition. Therefore,
FlR cells are inherently under glucose deprivation stress, but not amino acid
starved. In support of this possibility, our preliminary data suggest that while
mTORC1 inhibition is cytotoxic to FluR and not FluS cells (chapter IV), glucose
deprivation induces cell death in FluS and not FluR cells (chapter IV). We
propose that FluR cells have adapted themselves to survive metabolic stress by
constitutive activation of glucose deprivation response pathways, such as
autophagy. Therefore, they do not depend on exogenous glucose supply, as
reported recently for imatinib-resistant breast cancer cell lines (137).
The mTORC1 and autophagy pathways in response to pharmacological
inhibition of AMPK, and glucose starvation may be investigated, which will
provide important insight into the regulation of mTORC1 and autophagy by
AMPK. The TSC complex (levels of TSC complex components, phosphorylation
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Figure 6.2 The p62-mTORC1 connection (a) Levels of p62, as determined by
immunoblotting, in Nalm-6, Nalm-6-FluR, Reh, Reh-FluR cells. β-actin was used
as loading control. (b, c) Immunofluorescence staining showing colocalization of
mTOR/p62 in Nalm-6 and Nalm-6-FluR cells. (d, e) Nalm-6 cells were transfected
with GFP-Control or WT p62, and cell death was determined following 24 h Flu
treatment.
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Status of particularly AMPK target sites, i.e. T1227 and S1345, and Raptor
phosphorylation at S792 may be investigated.
An important question is how is mTORC1 able to maintain a critical
balance of metabolic demand with supply, in the absence of AMPK regulatory
check on it. The cross-talk between mTORC1 and AMPK may be further
investigated. In yeast, mTORC1 has been shown to inhibit Snf1 (AMPK
homologue), however, nothing is known in higher eukaryotes. Our hypothesis is
that in order to maintain energy homeostasis, mTORC1, infact, activates AMPK,
which then induces ULK-1 activation and autophagy in FluR cells. Investigation
of AMPK and autophagy pathway in response to pharmacological inhibition of
mTORC1, and amino acid starvation will provide important insight into the
regulation of mTORC1 and autophagy by AMPK.

6.2 Mechanism of co-activation of mTORC1 and autophagy in FluR cells
The co-dependence of FluR cells on mTORC1 activation and constitutive
autophagy is surprising as mTORC1 is known to inhibit autophagy by direct
phosphorylation of ULK-1 at S757 (Chapter 1). mTORC1 can spatially segregate
from the autophagy initiation complex by formation of specialized membrane
compartments, designated TOR-Autophagy Spatial Coupling Compartments
(TASCCs, Figure 6.3 a).(206) In that case, active mTORC1 is located at the
lysosome, as shown by co-localization of mTORC1 and LAMP2, with ULK-1
being excluded from TASCC.
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FluR cells have, indeed, a much higher co-localization of LAMP2 with
mTORC1 than with ULK-1 (Figure 6.3 b, c), suggesting that spatial uncoupling
between ULK-1 and mTORC1 due to TASCC formation may enable the ULK-1
complex to, at least partially, escape inhibition by mTORC1.
However, Ev was still able to induce autophagy and enhance autophagic
flux, as shown by LC3 II accumulation (Figure 6.3d) and p62 degradadation
which could be rescued by CQ (Figure 6.3d) in FluR cells. These data suggests
that autophagy, at least in part, was still regulated by mTORC1. However, the
level of autophagy induction in response to mTORC1 inhibition was considerably
reduced in FluR cells compred to Nalm-6 (Figure 6.3 d).
Thus, we propose that the autophagy inhibitory function of mTORC1 is
diminished in FluR cells, but may not be completely lost, due to partial spatial
uncoupling between mTORC1 and ULK-1. Consistent with the absence of
TASCCs in Nalm-6 cells (Figure 6.3 b, c), Ev induced higher LC3 II processing.
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Figure 6.3 The autophagy inhibitory function of mTORC1 is diminished in FluR
cells due to TASCC. (a) TOR-autophagy spatial coupling compartment (TASCC)
, a unique cytoplasmic compartment, which is highly enriched for both mTOR and
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(b,c)

Immunofluorescence staining showing colocalization of ULK1/LAMP2 and
mTOR/LAMP2 in Nalm-6 and Nalm-6-FluR cells. (d) Nalm-6 and Nalm-6-FluR
cells were pretreated with everolimus (Ev) for 24 h followed by 24 h CQ
treatment and lysates were analyzed for the indicated proteins.
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(Figure 6.3d) and p62 (Figure 6.3 d) degradation than in FluR cells. Overall our
data suggest that, there is an alternative mechanism of autophagy regulation, in
addition to mTORC1, in FluR cells. Under energy deficit conditions, AMPK is
known to activate ULK1 by either direct phosphorylation, i.e. AMPK-ULK1 or by
inhibiting mTORC1, i.e. AMPK-mTORC1-ULK1.
In our previous studies we have shown higher pULK1 S467, an AMPK
target site, in FluR cells. In addition, we showed that pULK1 S467 could be
inhibited using compound c, an AMPK inhibitor (148). In future studies, the levels
of mTORC1- and AMPK-dependent regulatory phosphorylation sites on ULK-1,
and the AMPK/ULK-1 interaction should be further investigated to fully
understand ULK-1 kinase activation (207). Downstream of ULK-1, mTORC1
directly phosphorylates and inhibits ATG14-containing VPS34 complexes.
Our data suggest that the BECN1-complex is inhibited by BCL-2 family
proteins in FluR cells (148). Whether inhibition of mTORC1 activates ATG14containing the VPS34 complex may be investigated. Further investigation of this
phenomena—mechanism and role of mTORC1-independent regulation of
constitutive autophagy in FluR cells will enhance our understanding of the
process of autophagy. We believe there must be a rationale behind existence of
two different paths from AMPK to ULK1. The two must differ in upstream inputs
and/ or in downstream consequences, which need to be evaluated more carefully
to fully appreciate the functions and regulation of autophagy.

6.3 BECN1-indepdendent autophagy in FluR cells
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Because basal autophagy was still observed in Fl-R cells despite BECN1
inhibition by MCL-1, it is likely that autophagy in Fl-R cells is independent of
BECN1. BECN1-independent autophagy has been reported in cardiac myocytes,
where protective autophagy was stimulated in an AMPK-dependent manner in
response to glucose deprivation or ischemia (173). Non-canonical, BECN1independent autophagy, dependent on ATG7 and ATG12/ATG5 has been
reported in various settings, including development and proliferation of late-stage
peripheral lymphocytes (208) and in response to apoptotic stimuli such as
staurosporine, resveratrol, or H2O2 (41). There are clear reports in the literature
showing autophagic cell death through BECN1 in canonical autophagy pathways
(119, 173). An important question is how can membrane nucleation happen
independently of BECN1?
Recently, a BECN1 homolog, BECN2, has been identified that associates
with VPS34 kinase and other members of the BECN1 complex, including VPS34,
BCL-2, and AMBRA1. BECN2 participates in autophagy independent of BCL-2
dissociation in response to starvation (209). In order to study whether basal or
inducible autophagy in FluR cells depends on BECN2, we investigated levels as
well as interactions of BECN2 with MCL-1 and BCL-2. Our data suggest that the
levels of BECN2 protein are the same in control and Flu-treated Nalm-6 and
Nalm-6-FluR cells (Figure 6.4a). Further, our immunoprecipitation studies
suggest that in FluR cells, BECN2 associates strongly with BCL-2 in untreated,
and BECN2/BCL-2 interaction does not change following Ev treatment (Figure
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6.4b). Thus, consistent with He et al. studies (209), BCL-2 doesnot seem to
regulate the function of BECN2.
In contrast, while we did not find any interaction between BECN2 and
MCL-1 in untreated FluR cells (Figure 6.4b), The BECN2/MCL-1 interaction was
observed following Ev treatment (Figure 6.4b). This suggests that constitutive,
prosurvival autophagy may require BECN2. However, following Ev treatment
which, in turn induces cell death in FluR cells (Chapter IV), MCL-1 dependent
inhibition of BECN2 blocks this prosurvival pathway. Thus, it will be interesting to
study further whether this switch between BECN1 and BECN2 binding to MCL-1
may be an important determinant of prodeath versus prosurvival autophagy.
How BECN2 and BECN1 interact with MCL-1 under various prodeath
stimuli in FluR cells, such as Ev and obatoclax can be investigated. Whether
BECN1 or 2 is in complex with Atg14L, UVRAG in Flu-sensitive versus FluR cells
may be studied to fully understand regulation of BECN-activity and the role of
BECN1/2-dependent autophagy in regulating Flu-resistance. In addition, ULK1
directly activates the VPS34 complex by phosphorylating AMBRA1 (210). Given
that AMBRA1 binds much tighter to BECN2 than to BECN1, it is possible that the
basal autophagy in FluR cells depends on AMBRA1 phosphorylation of the
BECN2-containing pool of VPS34 complex. The
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Figure 6.4 Constitutive prosurvival autophagy in FluR cells is mediated by
BECN2. (a) Nalm-6 FluR cells were treated with Flu for 24 h and cell lysates
were analyzed for the indicated proteins. (b) Nalm-6 FluR cells were treated with
Ev for 24 h, and MCL-1 and BCL-2 immunoprecipitates were analyzed for the
presence of the indicated proteins.
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effect of AMBRA1 kinase-dead mutant on autophagy in FluR cells may be
investigated.
Furthermore, although BECN1 plays a central role in autophagy in the
recruitment of other autophagy proteins to the pre-autophagosomal membrane
(121), are autophagy-independent functions of BECN1 1 can not be ruled out.
For example, heterozygous disruption of BECN1 in mice results in increased
spontaneous tumorigenesis (121). Further investigation is therefore needed to
clarify the role of BECN1- inhibition in mediating cell survival or cell death in
response to Fl.
Our studies suggest an intricate connection between mTORC1, metabolic
reprogramming, and autophagy pathways in FluR cells. Understanding the
precise regulatory mechanisms in the two-way flow of information among these
pathways will profoundly enhance understanding of drug resistance mechanisms,
and holds promise in the identification of novel therapeutic targets.
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‘’We come just after dawn. When resources are scarce, we attack the
weakest of us, the deformed and outcast. We invaginate us, drenching
our bodies with acid until we are unrecognizable. Then we eat us. We
are hungry. We are literally starving. This is not only how we survive;
it’s how we purge evil and stay pure.’’
-David Delp
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